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ABSTRACT 
Prostate cancer is the second leading cause of cancer-related deaths in 
men in the United States. The molecular pathogenesis of this disease includes 
genetic alterations, infection, and exposure to inflammatory or dietary oxidants. 
Recently, research has focused on the role of host defense peptides in tumor 
immunity. Defensins, a highly conserved multigene family of proteins that 
possess antimicrobial and antiviral properties, play an essential role in innate and 
adaptive immunity. These peptides are categorized into alpha- and beta-
defensins based upon the spacing and connection between the six conserved 
cysteine residues of the mature peptide. Human Beta Defensin-1 (hBD-1), an 
important component of the innate immune system, is frequently lost in malignant 
prostate tissue, while expression is maintained in adjacent benign regions. 
Several studies indicate there may be multiple tumor suppressor genes present 
within the 8p22-23 region in prostate carcinoma, an area where frequent genetic 
alterations occur. The high incidence of loss of hBD-1 expression in prostate 
cancer, along with its chromosomal location of 8p23.2, raised the possibility that 
it may playa role in tumor suppression. Our studies demonstrated that induction 
of hBD-1 expression results in significant changes in cell viability, membrane 
permeability, and the activation of caspase-mediated apoptosis in DU145 and 
PC3 human prostate cancer cell lines. However, no effect was observed 
following the induction of hBD-1 in LNCaP. To gain insight into the caspase-
mediated cell death, we analyzed the activation of specific caspases within the 
intrinsic and extrinsic pathway following the induction of hBD-1 expression. In 
xv 
DU145 and PC3 prostate cancer cell lines the activation of both apoptotic 
pathways was observed, specifically the activation of caspases 3, 8 and 9. 
However, no caspase activation was observed in the LNCaP prostate cancer cell 
line. Although our studies suggest that within our expression system and 
employed methodologies, hBD-1 does not exhibit a 'bystander effect' on 
neighboring cells, the results indicate a possible upward trend suggesting that 
hBO-1 may exhibit a 'bystander effect' under different conditions than those used 
in this study. Collectively, this data indicates the loss of hBD-1 in the area 
surrounding prostate cancer cells may create an environment that promotes the 




Prostate cancer continues to be a major burden on public health with high 
incidence of diagnosis and cancer-related deaths as compared to other forms of 
cancer. In South Carolina, it is the most commonly diagnosed cancer among 
males regardless of race 1. However, the incidence rate is almost two times 
higher in black males as white males 1. In addition, prostate cancer is the second 
leading cause of cancer-related deaths among South Carolina men with mortality 
rates due to prostate cancer being three times higher in black males 1. The 
current methods of early detection include the prostate specific antigen test 
(PSA), the digital rectal exam (DRE), and the diagnostic tissue biopsy. Although 
together these methods have helped diagnose prostate cancer at earlier stages 
in the general population over the years2, 3, they have marked deficiencies. 
Consequently, a better understanding of the molecular pathogenesis of prostate 
cancer may lead to the identification of pre-malignant molecular biomarkers that 
accurately predict neoplastic transformation within the prostate. 
The pathobiologyof prostate cancer is multifaceted due to the altered 
expression of numerous genes4, as well as environmental factors such as 
inflammation and dietS allowing for a multitude of potential biomarkers. A 
therapeutic target and potential biomarker of prostate cancer we are exploring is 
human Beta Defensin-1 (hBD-1). We previously demonstrated the cancer-
specific loss of innate immune peptide hBD-1, with a chromosomal location of 
8p23.2, in prostate cancer6. Several cytogenetic studies have demonstrated 
deletions on the short arm of chromosome 8 in a variety of cancers, including 
carcinomas of the bladder7, liver8 , ovary9, and prostate 10-16. Since the location of 
2 
tumor suppressor genes (TSGs) is suggested by the homozygous deletion of 
chromosomal regions17 , it has been proposed that the 8pter-8p23 region contains 
at least three separate tumor suppressor genes18-20 . The high incidence of loss of 
hBD-1 expression in prostate cancer, along with its chromosomal location, raised 
the possibility that it may be a tumor suppressor gene. 
In addition to the loss of TSGs, prostate tumor progression has also been 
associated with an increase in immune suppression in patients21 . In addition, it 
has been suggested that a tumor is capable of escaping destruction by the 
immune system via disruptions in the activation and suppression of immunity 
during tumor growth22 • Even though little is known about specific components of 
the immune system involved in tumor suppression, the loss of hBD-1 expression 
suggested that it may be a component of a tumor surveillance system that 
functions specifically through tumor immunity. Therefore, a better understanding 
of the expression pattern and role of hBD-1 in prostate cancer will give a more 
complete picture of precisely how this antimicrobial peptide is involved in the 
progression of prostate cancer. 
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CHAPTER 2 
BACKGROUND AND SIGNIFICANCE: 
A REVIEW OF THE LITERATURE 
4 
The Prostate Gland 
The prostate gland is a walnut-sized organ that functions as part of the 
male reproductive system. It is located in the pelvic area in front of the rectum 
and underneath the bladder (Figure 2-1). In addition, the prostate encompasses 
a portion of the urethra com ing from the bladder known as the prostatic urethra 
that merges with two ejaculatory ducts. 
Heterogenous in nature, the prostate is divided into glandular and non-
glandular tissues. The glandular components include the ducts and glands, while 
the non-gladular components consist of fibromuscular tissue. Pathologically the 
prostate is classified by four zones: the peripheral zone, the central zone, the 
transition zone, and the anterior zone23• The peripheral zone is the closest to the 
rectum and accounts for the largest portion of prostatic volume. This zone is 
where the largest percentage of prostate cancers originate23 • Comprising the 
second largest portion of the prostate volume, the central zone surrounds the 
ejaculatory ducts. The smallest and innermost glandular component of the 
prostate, the transition zone, surrounds the prostatic urethra and is rarely 
associated with cancer. The anterior zone, closest to the abdomen and 
composed mainly of fibromuscular tissue, consists of the non-glandular 
components of the prostate. 
In younger males the prostate is generally healthy, however, as a man 
ages changes begin to occur within the gland (Figure 2-2). These changes 
mainly present in a clinical setting as one of three main prostate 
5 
Figure 2-1: Illustration of the location of the prostate gland. The prostate is 
a part of the male reproductive system that encompasses a portion of the 
prostatic urethra. (adapted from www.cancer.gov) 
Figure 2-1: Illustration of the location of the prostate gland. 
(adapted from www.cancer.gov) 
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Figure 2-2: Schematic of changes from normal prostate to prostate cancer. 
A histologic account for the changes from a healthy prostate typical of a young 
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Figure 2-2: Schematic of changes from normal prostate to prostate cancer. 
(adapted from Nelson et al 200326) 
9 
disorders: prostatitis, hyperplasia or carcinoma. The first of these changes is 
prostatitis, or inflammation of the prostate tissue, which manifests as difficult or 
painful urination. It is classified as acute or chronic based upon a combination of 
clinical features and microscopic examination. Although the cause is often 
unknown, it is sometimes a result of a bacterial organism associated with other 
urinary tract infections21. 
Another change that can occur with age in the prostate is enlargement of 
cells within the transition zone, also know as benign prostatic hyperplasia 
(BPH)24. As the prostate enlarges, it begins to squeeze the urethra which may 
cause urinary problems by slowing or obstructing the flow of urine from the 
bladder to the penis. Additionally, BPH can result in retention of urine in the 
bladder due to the inability to completely empty it. Neither prostatitis nor BPH 
are known to cause cancer, however, men with one or both of these conditions 
may develop prostate cancer as well. 
Prostate Cancer 
Prostate cancer remains the most common malignancy, excluding skin cancer, 
and the second leading cause of cancer related deaths in men in the United 
5tates25 . Risk factors for prostate cancer that have long been recognized include 
age, race, androgens and a variety of lifestyle factors, such as diet. In addition, 
there is a strong hereditary component in the risk of prostate cancer 
development. Steinberg et al. (1990) reported that the number of affected first-
10 
degree relatives significantly increased the risk, whereas there was only a 
marginal increase in risk if distant relatives were affected27. 
More recently, molecular genetic studies of fam ilial prostate cancer led to 
the identification of numerous genes and genetic alterations that has greatly 
enhanced our understanding of prostate cancer development and progression4. 
The most thoroughly investigated of these is hereditary prostate cancer (HPC1 
gene)28. In addition, it has been proposed that RNASEL, MSR1, AR, CYP17, 
SRD5A2, and a variety of other genes are potential contributors to the risk of 
prostate cancer developmenf9-36. Although the exact mechanism underlying 
prostate tumorigenesis is unknown, it is known that the clinical outcome of a 
prostate cancer patient is closely related to tumor grade and stage with poorly 
differentiated tumors having a poor prognosis37. 
Molecular Pathogenesis of Prostate Cancer 
The molecular pathogenesis of prostate cancer involves a progression 
through a series of pre-malignant changes that ultimately lead to uncontrolled 
cellular division resulting in malignancy (Figure 2-3). There is an abundance of 
evidence suggesting a key component of this progression includes the 
transformation of normal epithelium to prostate inflammatory atrophy (PIA), a 
focal area of proliferating cells accompanied by inflammation38. PIA lesions 
occur in the peripheral zone of the prostate where most prostate carcinomas 
originate38, 39 and are often located adjacent to areas of prostate intraepithelial 
neoplasms (PIN), a known precursor to prostate cancer40. 
1 1 
Figure 2-3: Pathogenesis of prostate cancer. The effects of age and the 
accumulation of numerous genetic and environmental insults that contribute to 
the molecular pathogenesis of prostate cancer. (adapted from Nelson et al 
20044°) 
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Figure 2-3: Pathogenesis of prostate cancer. 
(adapted from Nelson et al 20044°) 
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Several studies have identified additional changes in prostate tissue as it 
undergoes a transition from PIA to PIN including p53 mutations41 and "-class 
glutathione S transferase (GSTP) hypermethylations38, 42, GSTs, long 
recognized to protect against cancer, are a fam ily of enzymes that prevent DNA 
damage by serving as a catalyst for the scavenger glutathione to detoxify 
environmental carcinogens and oxidants43, 44, The loss of GSTP1 expression 
due to hypermethylation and the inflammatory state of PIA lesions have been 
associated with high grade PIN26, 40,45,46, 
The term PIN refers to established morphological criteria that simply 
defined describes the presence of individual, atypical cells resulting in the 
enhancement of the normal glandular architecture4, Multiple studies indicate that 
areas within the prostate that demonstrate the histological changes of PIN are 
designated as low or high grade based upon the findings47• It is important to note 
that current models of the molecular pathogenesis of prostate cancer recognize 
PIN as a precursor to the development of prostate cancer48• 
As in other forms of cancer, prostate neoplasms have been extensively 
studied for genetic alterations and candidate susceptibility genes49 , Loss of 
heterozygosity (LOH) describes the loss of one allele in the tumor cells of a 
heterozygous individual. LOH studies in various types of cancer have identified 
the loss of putative tumor suppressor genes5, 6, Although the underlying 
mechanism of LOH is not completely understood, several proposed mechanisms 
include the loss of whole chromosomes, partial chromosome deletion, 
disproportionate translocation and mitotic recombination36, 40, 50-53, Studies have 
14 
shown that chromosome 8 possesses the most frequent cytogenetic changes 
observed in prostate cancer patients54, 55. 
To date, at least three host immune response genes are emerging as 
prostate cancer susceptibility genes: RNASEL, MSR1, and hBD-1 35, 36. 
RNASEL, a ribonuclease activated in the presence of viral infections, functions to 
degrade cellular and viral RNA. Studies have identified three mutant alleles of 
RNASEL that result in a defective protein and have been associated with 
increased prostate cancer risk50-52 • 
Another immune response gene that has emerged with a strong 
association to prostate cancer development is MSR1 56, 57. Located on 8p22, the 
MSR1 gene encodes a macrophage scavenger protein that can bind various 
ligands, including bacteriallipopolysaccharides26. It appears the expression of 
MSR1 is limited to macrophages at sites of inflammation within the prostate. 
Lastly, the cancer specific loss of hBD-1 has been shown in prostate and 
renal carcinomas58, 59. In addition, several studies have demonstrated that the 
over-expression of this peptide results in cell death in prostate, bladder, and 
renal cancer celilines6o-62 • Although the exact mechanisms of these genes 
involvement in prostate cancer pathogenesis are unknown, the data suggest it 
involves host defense against inflammatory damage. Moreover, the genetic 
changes observed in and molecular pathogenesis of prostate cancer provide 
ample evidence for the role prostate inflammation may play in the development 
of prostate cancer. 
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Prostate Cancer Detection 
Since the mid-1990's, the measurement of prostate specific antigen (PSA) 
levels has been one of the main screening methods for prostate cancer. PSA is 
a serine protease normally present in the acidic fluid secreted in the semen. On 
average, a PSA level is normal if it falls below 4ng/ml and high if it is above 
10ng/ml. Elevated serum PSA levels or the palpitation of a tumor growth during 
a digital rectal exam (ORE) are considered to be prognostic indicators of prostate 
carcinoma. 
Although these methods have served to increase the detection of prostate 
cancer, they have recognized limitations. The DRE, a quick, but rather invasive 
physical exam, allows for an area of detection limited to digital palpitation, thus, 
leaves room to miss a tumor. While the PSA screening serves to detect potential 
prostate cancer missed by the DRE, it has inherent problems with sensitivity and 
standardization. For example, an increase in PSA levels can be a result of other 
abnormalities of the prostate such as prostatitis or BPH63 . Therefore, it is 
necessary to perform a transrectal biopsy to confirm a clinical diagnosis. Since 
none of the methods to date have proven to definitively diagnose prostate cancer 
alone, the emergence of new molecular targets may prove to identify early 
alterations in prostate cells accurately and efficiently with minimal invasiveness. 
Prostate Cancer Grading System 
Several histopathological grading systems for prostate cancer have been 
designed. However, the Gleason grading system, named after D.F. Gleason, 
16 
was recommended by a WHO consensus conference in 1993 and is currently the 
principal grading system used64. The Gleason grading system defines the 
histological patterns with decreasing differentiation in glandular architecture of 
the tissue65, 66. To obtain a Gleason score, the primary and secondary, i.e. most 
prevalent and second most prevalent, patterns are added66. Gleason pattern 1 
tumors are very rare and composed of a well confined nodule of separate, tightly-
associated glands that do not infiltrate into adjacent benign tissue67. Gleason 
pattern 2 describes rounded glands with smooth ends that are loosely arranged 
and lack the uniform size67. The most common is Gleason pattern 3, in which 
there is more glandular infiltration of adjacent benign tissue, as well as a more 
marked variation of distance between them 67. In Gleason pattern 4, the glands 
are fused and no longer have stroma separating them, while Gleason pattern 5 
describes almost a complete loss of glandular lumina67. 
The Defensin Family 
Antimicrobial peptides (AMPs) are found in an extensive array of 
eukaryotic organisms68 and are classified into categories based upon their 
structural characteristics69 . One important category of AMPs in humans is the 
defensin family70-72. Defensins, a family of 3-4 kDa cationic peptides, are 
cysteine rich amphipathic peptides involved in innate immunity73. They can be 
classified into a-, p- and 9-defensins based on the pattern of six conserved 
cysteine residues and the precursor gene structure74. a-defensins are normally 
abundant in the microbicidal granules of polymorphonuclear leukocytes and have 
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been identified in the Paneth cells of the human intestine75. p-defensins have 
been identified in bovine tracheal epithelium 76 and the epithelial surfaces of 
respiratory, genitourinary, and gastrointestinal tracts77, 78. Although a-defensins 
exhibit broad spectrum antimicrobial activity against both Gram-negative and 
Gram-positive bacteria, fungi, and enveloped viruses79, p-defensins are mainly 
active against Gram-negative bacteria and yeast59, 60, 80. 
To be classified as a p-defensin, the peptide must consist of 36 or more 
amino acids with a primary structure that consists of the following identifiable 
disulfide bond sequence 1-5,2-4, and 3_673,81-83. Other residues that are 
conserved among the p-defensins include (using hBD-1 numbering): Gly10, a 
cationic residue at position 13, Glu21, and hydrophobic residues at positions 24 
and 3681 . The carboxy terminal end of the four most studied hBDs, hBD-1 to 
hBD-4, contains a cluster of cationic residues (Lys and Arg). The aggregation of 
positive charges proves to be important for antimicrobial activity73. 
To date, six hBDs (hBD1-6) have been identified that are either 
constitutively secreted, or inducibly expressed for secretion, at the epithelial cell 
surface84, 85. The first human p-defensin, hBD-1, was purified from the plasma of 
patients with renal disease in 199586,87. Since then, several other p-defensins 
have been isolated or identified through genetic analysis. hBD-2 was purified 
from the lesions of psoriatic skin88, 89, while hBD-3 was isolated from psoriatic 
scales90, 91. The remaining three p-defensins identified to date, hBDs 4-6, were 
originally reported based upon genome analysis62, 75. Searches of the human 
genome have recently revealed about 40 potential coding regions for p-defensins 
18 
(DEFBs)91 suggesting the possibility that numerous hBDs have yet to be isolated 
and identified. 
Currently there are two postulated mechanisms of how host defense 
peptides exhibit the antibacterial properties they posses (Figure 2_4)92: the barrel 
stave model and the carpet model. The models are based upon the selectivity of 
the peptide for its binding surface. 
(1) Barrel stave model: In this model, multimeric pores form 
as a result of the hydrophobic bond between the peptide and the 
bacterial cell membrane in a non-selective manner91. More 
specifically, the hydrophobic surface of lytic peptide monomers 
interacts with the lipid core of the bacterial membrane causing the 
hydrophilic surface to point inward forming an aqueous pore. 
Recruitment of additional monomeric peptides to the site leads to 
an increase in the pore size eventually resulting in membrane 
depolarization ad cell death93. 
(2) Carpet model: This model describes the cell selective 
electrostatic interaction of the AMPs to the surface of the outer 
membrane. The peptides cover the membrane surface like a 
carpet until reaching a threshold concentration which enables the 
peptides to permeate the membrane. Permeation results in an 
intermediate formation of transient pores, known as 'toroidal' pores, 
that span the distance of the membrane95, 96. Cell death follows 
19 
Figure 2-4: Illustrations of the two mechanisms of membrane lysis by host 
defense peptides. Peptides that are not cell-selective bind to all types of 
membranes and form transmembrane pores via the 'barrel-stave' mechanism 
resulting in membrane depolarization followed by cell death. Peptides that are 
cancer cell-selective bind in the first step mainly by electrostatic interactions and 
align parallel to the outer membrane surface (step 1) and cover it in 'carpet-likeJ 
manner. After a threshold concentration of peptides has been reached (step 2), 
the peptides permeate the membrane, which, in most cases, is followed by 
membrane disintegration and micellization. An intermediate step is the formation 
of transient pores. These pores were described as !toroidal' pores for peptides 
that are long enough to span the membrane. These pores might also lead 
directly to cell death. The figure also shows B 16 me\anoma ce\\s treated w\th a 
lytic peptide labeled with rhodamine before (picture on the left showing the intact 
cell) and after (pictures on the right showing the remaining nucleus) a threshold 
concentration has been reached. (adapted from Papo and Shai 200594) 
"Barrel-stave" Model 
.. embrnne depohuization 
nnd Cell death 





and Cell death 
Membr,one depolQrization 
and Cell death 
Figure 2-4: Illustrations of the two mechanisms of 
membrane lysis by host defense peptides. (adapted from 
Papo and Shai 200594) 
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pore formation due to the disintegration of the membrane and 
micellization97,98. 
The proposed mechanism of p-defensin action against invading pathogens 
follows the carpet model with electrostatic interactions occurring between the 
basic defense peptides and the acidic phospholipids on the bacterial 
membrane99. Although the basic carpet model is accepted, several views exist 
that expound upon the mechanistic details of the process. 
As previously mentioned, an AMP selectively targets based upon the 
composition of the cell membrane. Bacterial cell membranes consist of 
phospholipids with negatively charged outer leaflets, while the outer leaflet of 
eukaryotic cell membranes contains phospholipids consisting of mainly neutral 
choline91 . It has been shown that defensins selectively target tumor cells 
compared to non-transformed cells100. There are several possible explanations 
for the selective targeting of tumor cells. Compared to a normal eukaryotic cell, a 
transformed cell has a slightly negative charge on the outer membrane due to the 
presence of phosphatidylserine and O-glycosylated mucine 101. In addition, a 
tumor cell exhibits a partial loss of its lipid asymmetry, thus, contributing to the 
slight negative charge it develops102, 103. The transition from neutral to negatively 
charged allows the tumor cell to be more susceptible to the lytic effects of the 
peptides without harmful effects to surrounding normal cells. Another 
explanation for the difference in susceptibility between tumor and normal cells in 
response to lytic peptides may be the presence of more microvilli which provides 
an increased surface area on tumor cells that allows for the binding of a greater 
22 
number of peptides94, 104, 105. A final explanation for the difference may be that 
tumor cells have a higher negative potential than non-transformed cells85. 
Numerous reports indicate the importance of the antimicrobial action that 
defensins exhibit as part of the immune response. A demonstration of their 
significance centers on a correlation between defensin expression and the 
incidence of infection in humans 106,107. It was recently reported that a decrease 
in p-defensin expression in atopic dermatitis contributed to the presence of skin 
infections 106,108. Similarly, other reports indicate a reduction in defensin 
expression contributes to the chronic bacterial infections experienced by cystic 
fibrosis patients6, 96, 109, 110. 
Although the main function of defensins is to serve as the initial response 
to a pathogen as a critical part of innate defense111 , they exhibit many other 
properties 112(Figure 2-5). Studies have been conducted to investigate defensin 
mediated immune activation, IL-8 production, and chemotaxis of iDG and T-
cells 113. It has also been shown that there are inter-individual variations in 
expression of p-defensins modulated in response to infection and 
inflammation 114. 
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Figure 2-5: Diagram of the various biological functions of p-defensins. 
Peptides of the p-defensin family mediate and participate in a variety of biological 
functions. These processes are both microbicidal and non-microbicidal in nature. 
(adapted from Kluver, et al 2006106) 
Figure 2-5: Diagram of the various biological functions of p-defensins. 
(adapted from Kluver et al. 2006106) 
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The field of tumor immunity is gaining more attention lately as the 
convergence of tumorigenesis and immunity has created an exciting and 
promising area of research. It has been shown that in oral squamous cell 
carcinoma, lung cancer, basal cell carcinoma, renal and prostate carcinomas P-
defensins exhibit differential gene expression profiles115, 116. The manipulation of 
the immune system to destroy tumor cells was initially described by Morales et 
a/. in 1976 with the anti-tumor effect of Mycobacterium bovis Bacillus Calmette-
Guerin (BCG) in bladder cancer116. Recently, Ludwig et a/ published data 
supporting the antitumoral activity of BCG therapy is due to the response of 
cytokines to BCG, ultimately leading to the upregulation of tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL)77, 117. TRAIL has been shown to 
induce apoptosis in multiple cancer cells without exhibiting cytotoxicity to normal 
cells22• 
In addition, growing evidence supports anti-cancer therapies using 
monoclonal antibodies (mAbs) to specifically target cancer cells without 
disrupting surrounding normal tissue118. Other immune-based therapies, such as 
cytokine and vaccine approaches, have been used in clinical trials as a treatment 
for a variety of cancers, including prostate cancer78. Fong et al. (2001) have 
shown that antigen-specific antitumor immune response can be initiated through 
the use of dendritic cells as a vector for presenting tumor antigens81 , 85. 
The Gj-protein-coupled receptor, CCR6, mediates the recruitment of iDCs 
and memory T cells for p-defensins indicating their activity in adaptive immunity. 
Additional studies into the adaptive immune component of p-defensins have 
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demonstrated they are capable of facilitating the delivery of antigens to receptors 
on iDCS81 . This results in an antigen-specific immune response mediated by the 
presentation of the tumor antigen to mature dendritic cells and T cells via MHC II 
molecules. However, evidence exists that demonstrates dendritic cell infiltration 
is decreased in patients with advanced prostate cancer, thus suggesting a 
possible mechanism by which immunity-mediated destruction is suppressed in 
prostatic tumors 106. 
Human Beta Defensin-1 
Human p-defensin-1 was first isolated as a 36 amino acid peptide from 
human plasma ultrafiltrates 119 and has been mapped to chromosome 8p23.275, 76. 
The DEFB1 gene has a simple structure consisting of two exons flanking an 
intron that spans 6962 bp 14,78,91,94,106 (Figure 2-6). The full length cDNA for 
hBD-1 contains only 362 bases78, 119 (Accession No. X92744). A characteristic 
endoplasmic reticulum targeting signal sequence with signal peptidase cleavage 
sites between Gli1/Gli2 and Ser16/Glu17, a short (11 or 16 amino acid) pro-
piece, and a sequence for the mature hBD-1 peptide are encoded in the open 
reading frame78, Specifically, the 128 bp exon 1 encodes the prepro-piece, 
which is about 68 amino acids in length, and the signal sequence78, 88,119. Exon 
2, 234 bp in length, encodes the mature hBD-1 peptide78• 91 , A GC box is found 
at position -217 bp and a TATA box sequence are located at position -34 bp 
relative to the first cDNA base78• 
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Figure 2-6: Signature motif for p-defensin genes. The structural organization 
of the 3-defensin gene includes two exons surrounding a variably sized intron. 
Some degree of nucleotide identity is found among the defensins in exon 1, 
which encodes the signal sequence 14. Exon 2 encodes the propeptide and 
mature peptide. (adapted from Weinberg et al. 199812°) 
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Figure 2-6: Signature motif for beta-defensin genes. 
(adapted from Weinberg et al. 1998121 and Bals et al. 2000122 ) 
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The proteolytic processing of varying functional domains of a protein 
generally occurs as needed during the maturation process. Several studies have 
identified naturally occurring N-terminally truncated molecular variants of hBD-1 
from 36-47 amino acids in length in blood and urine74, 119. Mass spectrometry 
measured the molecular masses of 3928 Da for the native peptide and 4276 Da 
for the reduced and alkylated peptide81 . 
With the initial isolation of hBD-1 from human filtrates, it was estimated 
that the peptide is present in nanomolar concentrations81 . Although it has been 
shown that hBD-1 has cytotoxic potential toward mammalian cells106,119, 
constitutive expression at basal levels is not sufficient to independently lyse cell 
targets. It is known that hBD-1 is a constitutively expressed peptide in the 
epithelia of numerous tissues, including gingival, lung, digestive, kidney, and 
prostate74, 82,123,124. In addition, hBD-1 is the only human beta defensin the gene 
expression of which is not induced by inflammatory stimuli, such as IL-8 and 
LPS78, 125, 126. 
Previously Donald et a/ demonstrated the cancer specific loss of hBD-1 
expression in clinical prostate and renal carcinoma samples6. In addition, IHe 
analysis indicated the loss of expression occurs as early as PIN, a precursor to 
prostate carcinoma, with normal glandular staining observed in adjoining benign 
tissue (Figure 2-7)6. Overall, they found benign epithelium stained positive for 
hBD-1 expression in both the kidney and prostate, while adjacent malignant 
epithelium exhibited little to no stain for hBD-1 in 90% and 82% of the samples, 
respectively (Figure 2-8)6. 
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Figure 2-7: IHC analysis of hBD-1 in the prostate. A, Normal prostate 
expresses hBO-1 (black arrow), while adjacent malignant tissue does not (red 
arrow). B, PIN exhibits loss of hBD-1 expression (red arrow), while expression is 
maintained in a normal gland (black arrow). C, Malignant prostate tissue shows 
the absence of hBO-1 stain (red arrow), while normal glands are positive for 
hBD-1 (black arrow). (adapted from Donald et a/20036 ) 
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Figure 2-7: IHC analysis of hBD-1 in the prostate. 
(adapted from Donald et a/20036) 
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Figure 2-8: Staining intensities of hBD-1 protein in kidney and prostate 
cancers clinical samples. A, Prostate cancer (n=1 00); B, renal cancer (n=48). 
Each graph summarizes the results of IHe staining intensity of two pathologists. 
The staining intensities were determined on an individual basis according to the 
percentage of malignant cells positive for hBD-1 expression as follows: 
Negative= no positive cells; Weak= 1 % to 250/0; Moderate= 26% to 750/0; Strong= 
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Figure 2-8: Staining intensities of hBD-1 protein in kidney and prostate 
cancers clinical samples. (adapted from Donald et a/20036 ) 
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As mentioned earlier ,B-defensins function as antimicrobial or chemotactic 
agents. However, numerous studies have demonstrated the rather weak 
antimicrobial119 and chemotactic77. 127 activities of hBD-1 as compared to other 
family members suggesting other biological functions. Recently, the strong 
cytotoxicity of hBD-1 in vitro against multiple cancer cell lines has been 
demonstrated56, 57. Given that endogenous hBD-1 is constitutively expressed by 
normal cells without cytotoxicity, it may be distinct phenotypic characteristics that 
render tumor cells sensitive to the cytotoxiC effects of hBD-1. Thus, it is a 
plausible suggestion that hBD-1 plays a critical role in tumor immunity. 
Hypothesis, Specific Aims and Significance 
Although it is known that innate immunity is key for protecting the body 
against foreign agents such as bacteria, little is known about elements of the 
innate immune system that have anti-tumor activity. hBD-1, an important 
component of the innate immune response, is lost at high frequencies in 
malignant prostatic tissue, while expression is maintained in adjacent benign 
regions 14. In prostate carcinoma, frequent genetic alterations occur in the 8p22-
23 region and several studies indicate there may be multiple tumor suppressor 
genes present within this region 21 , 128.129, The high incidence of loss of hBO-1 
expression in prostate cancer, along with its chromosomal location of 8p23.2, 
raised the possibility that it may playa role in tumor suppression. Therefore, we 
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hypothesize that hBD-1 may be a tumor suppressor gene involved in tumor 
immunity in prostate cancer. 
To test this hypothesis, we propose the following specific aims: 
Specific Aim 1: Characterize the effects of ectopic expression of hBO-1 on 
prostate cancer cell lines. 
The hBD-1 gene has been cloned into an inducible expression system that will 
be utilized to characterize its function in prostate cancer cells. This will be 
determined by examining the effect hBD-1 has on cell viability, as well as 
morphological changes to cell membrane and annexin Vand propidium iodide 
uptake in cells induced for hBD-1 expression. 
Specific Aim 2: Determine the cellular mechanisms associated with the 
effects of hBD-1 on prostate cancer cells. 
The inducible hBD-1 expression system will be utilized to determine if hBD-1 
induces apoptosis in prostate cancer cells. This will be determined by analysis of 
caspase activation and changes in the expression of various regulators of 
apoptosis, such as BCL-2 family members and AKT. 
Specific Aim 3: Determine the role of hBD-1 in the progression of prostate 
cancer. 
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Here, we will determine if hBD-1 functions as a component of a tumor 
surveillance system by acting on neighboring cells via a 'bystander effect.' The 
cell culture supernatant exposed to normal prostate epithelial cells will be 
harvested and analyzed for secretion of hBD-1 peptide. Additionally, the 
expression of hBD-1 will be profiled in prostate tissue samples from benign, 
tumor and areas of PIN. 
Significance: 
Numerous studies have indicated the importance of chromosome 8 
instability in prostate tumorigenesis22 . The goal of this proposal is to characterize 
the function of hBD-1, an important component of the innate immune response 
that is lost in prostate cancer. Since the gene encoding hBD-1 is located within a 
region of chromosome 8p thought to contain three separate tumor suppressor 
genes130, the studies will focus on hBD-1 as a potential tumor suppressor in 
prostate cancer. The proposed aims will allow further understanding how hBD-1 
functions in prostate cancer and may eventually aid in the development of 
strategies to prevent prostate cancer incidence and mortality. 
37 
CHAPTER 3 
CHARACTERIZATION OF THE EFFECTS OF HBD-1 
ON PROSTATE CANCER CELLS 
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INTRODUCTION 
Prostate cancer is the most common non-cutaneous malignancy in 
American men and is the second leading cause of cancer-related death in males 
in the United States 131. The clinical outcome of prostate cancer is closely related 
to tumor grade and stage, with poorly differentiated tumors having a poor 
prognosis 131. Prostate tumor progression has been linked to an increase in 
immune suppression in prostate cancerpatients6 • It has also been suggested 
that an imbalance between immune activation and suppression during tumor 
growth allows a tumor to escape immune destruction 132. However, little is known 
about specific components of the innate immune system that playa role in 
prostate tumor suppression. 
The defensin genes, a family of 3-4 kDa polycationic peptides clustered on 
the short arm of chromosome 8 at segment 8p22-8p23, have been shown to act 
as antimicrobial agents by disrupting membrane integrity resulting in cell lysis 
and death6 . The involvement of defensin proteins in cytotoxicity and cytolysis, 
with respect to tumor immunity, is gaining more attention. Human beta defensin-
1 (hBD-1) is a potent "microchemokine" that attracts immature dendritic cells and 
memory T cells via a specific interaction with the chemokine receptor CCR691 . It 
is through this action that p-defensins are thought to play an important role in 
both innate and adaptive immune responses, but their role in prostate tumor 
progression remains unclear133. We have previously shown that the expression 
of hBD-1 is lost or suppressed in 820/0 of malignant prostate tissue, whereas 
benign tissue generally expressed moderate to high levels of this peptide 134. 
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Although hBD-1 expression is lost at high frequency in prostate cancer, little is 
known about its function or whether this phenomenon contributes to prostate 
tumor progression. 
These observations led to the hypothesis that hBD-1 may have anti-tumor 
activities and that its loss may contribute to prostate tumorigenesis. In this study, 
we test this hypothesis by assessing the function of hBD-1 in prostate cancer. 
Initial screening for hBD-1 expression revealed high levels of hBD-1 expression 
in benign prostatic tissue and the prostate primary culture hPrEC. However, we 
observed a loss of hBD-1 expression in adjacent malignant prostatic tissue, as 
well as in DU145, PC3 and LNCaP prostate cancer cell lines. Our functional 
data show that the induction of hBD-1 expression results in rapid cell death in the 
late-stage prostate cancer cell lines, PC3 and DU145, but had no effect on the 
early-stage prostate cancer cell line, LNCaP, or normal prostate epithelial cell 
line, hPrEC, cell viability. With this, we provide the first experimental evidence 
that hBD-1 may playa specific role in tumor suppression of advanced prostate 
cancer. Furthermore, these data support the potential utility of hBD-1 as a 
therapeutic agent for late-stage prostate cancer without cytotoxic effects to the 
host. 
MATERIALS AND METHODS 
Cell culture 
The prostate cancer cell lines were obtained from the American Type 
Culture Collection (Manassas, VA) (Table 1). DU145 cells were cultured in 
DMEM medium, PC3 and PC3/AR+ were grown in F12 medium, LNCaP were 
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grown in RPMI medium (Life Technologies, Inc., Grand Island, NY). Growth 
media for all three lines was supplemented with 10% (v/v) fetal bovine serum 
(Life Technologies). The hPrEC primary culture was obtained from Cambrex Bio 
Science, Inc. (Walkersville, MD) and cells were grown in prostate epithelium 
basal media (Table 1). All cell lines were maintained at 37° C and 5% CO2 . 
Tissue Samples and Laser Capture Microdissection 
Prostate tissues were obtained from patients who provided informed consent 
prior to undergoing radical prostatectomy. Samples were acquired through the 
Hollings Cancer Center tumor bank in accordance with an Institutional Review 
Board-approved protocol. This included guidelines for the processing, 
sectioning, histological characterization, RNA purification and PCR amplification 
of samples. Prostate specimens received from the surgeons and pathologists 
were immediately frozen in OCT compound. Each OCT block was cut to produce 
serial sections which were stained and examined. Areas containing benign cells, 
Prostatic Intraepithelial Neoplasia (PIN), and cancer were identified and used to 
guide our selection of regions from unstained slides using the Arcturus PixCell II 
System (Sunnyvale, CA). Caps containing captured material were exposed to 20 
IJI of lysate from the Arcturus Pica Pure RNA Isolation Kit and processed 
immediately. RNA quantity and quality was evaluated using sets of primers that 
produce 5' amplicons. The sets include those for the ribosomal protein L32 (the 
3' amplicon and the 5' amplicon are 298 bases apart), for the glucose phosphate 
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Table 1: Prostate cell lines. 
Normal Cancer Site of Metastasis 
DU145 Brain carcinoma 
hPrEC 
PC3 Bone adenocarcinoma 
LNCaP 
Left supraclavicular lymph node 
carcinoma 
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isomerase (391 bases apart), and for the glucose phosphate isomerase (842 
bases apart). Ratios of 0.95 to 0.80 were routinely obtained for these primer sets 
using samples from a variety of prepared tissues. Additional tumor and normal 
samples were grossly dissected by pathologists, snap frozen in liquid nitrogen 
and evaluated for hBD-1 expression. 
Cloning of hBD-1 Gene 
hBD-1 cDNA was generated from RNA by reverse transcription-PCR 
using primers generated from the published hBD-1 sequence (Accession No. 
U50930)62. The PCR primers were designed to contain Clal and Kpnl restriction 
sites. hBD-1 PCR products were restriction digested with Clal and Kpnl and 
ligated into a T A cloning vector. The T AlhBD-1 vector was then transfected into 
the XL-1 Blue strain of E. coli by heat shock and individual clones were selected 
and expanded. Plasm ids were isolated by Cell Culture DNA Midiprep (Qiagen, 
Valencia, CA) and sequence integrity verified by automated sequencing. The 
hBD-1 gene fragment was then ligated into the pTRE2 digested with Clal and 
Kpnl, which served as an intermediate vector for orientation purposes. The 
pTRE2/hBD-1 construct was digested with Apa/ and Kpnl to excise the hBD-1 
insert. The insert was ligated into plND vector of the Ecdysone Inducible 
Expression System (Invitrogen, Carlsbad, CA) also double digested with Apal 
and Kpnl. The construct was again transfected into E. coli and individual clones 
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were selected and expanded. Plasmids were isolated and sequence integrity of 
plNDI hBD-1 was again verified by automated sequencing. 
Transfection 
Cells were seeded into appropriate dishes at least 5 hours prior to 
transfection. Next, the cells were co-transfected using Lipofectamine 2000 
(Invitrogen) with 2 pg/cell of pvgRXR plasmid, which expresses the heterodimeric 
ecdysone receptor, and 2 pg/cell of the pIND/hBD-1 vector construct in Opti-
MEM media (Life Technologies, Inc.). As a control, cells were transfected with 4 
pg/cell of the pvgRXR plasmid. Transfection efficiency was determined by 
transfecting cells with 4 pg/cell of a pcMV-GFP vector (gift from Christina 
Voelkel-Johnson laboratory, MUSC, Charleston, SC) and expressed as percent 
gated following FACS analysis. 
Immunocytochemistry 
In order to verify hBD-1 protein expression, DU145 and hPrEC cells were 
seeded onto 2-chamber culture slides (BD Falcon, USA) at 1.5-2 x 104 cells per 
chamber. DU145 cells transfected with pvgRXR alone (control) or with the hBD-
1 plasmid were induced for 18 hours with media containing 10 lJM Pon A, while 
untransfected cells received fresh growth media. Following induction, cells were 
washed in 1 x PBS and fixed for 1 hour at room temperature with 4% 
paraformaldehyde. Cells were then washed 6 times with 1 x PBS and blocked in 
1 x PBS supplemented with 20/0 BSA, 0.8% normal goat serum (Vector 
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Laboratories, Inc., Burlingame, CA) and 0.4% Triton-X 100 for 1 hour at room 
temperature. Next, cells were incubated overnight in primary rabbit anti-human 
BD-1 polyclonal antibody (PeproTech Inc., Rocky Hill, NJ) diluted 1 :1000 in 
blocking solution. Following this, cells were washed 6 times with blocking 
solution and incubated 1 hour at room temperature in Alexa Fluor 488 goat anti-
rabbit IgG (H+L) secondary antibody at a dilution of 1:1000 in blocking solution. 
After washing cells with blocking solution 6 times, coverslips were mounted with 
Gel Mount (Biomeda, Foster City, CA). Finally, cells were viewed under 
differential interference contrast (DIC) and under laser excitation at 488 nm. The 
fluorescent signal was analyzed using a confocal microscope (Zeiss LSM 5 
Pascal) and a 63x DIC oil lens with a Varia 2 RGB Laser Scanning Module. The 
digital images were exported into Photoshop CS Software (Adobe Systems) for 
image processing and hard copy presentation. 
RNA Isolation and Quantitative RT-PCR 
QRT-PCR was performed as previously described135. Briefly, total RNA 
(0.5 J..Ig per reaction) from both sources was reverse transcribed into cDNA 
utilizing random primers (Promega). Two-step QRT -PCR was performed on 
cDNA generated using the MultiScribe Reverse Transcriptase from the TaqMan 
Reverse Transcription System and the SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA). The primer pairs for hBD-1 and c-MYC were 
generated from the published sequences (Table 2). Forty cycles of PCR were 
performed under standard conditions using an annealing temperature of 56.4° C 
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for hBD-1 and c-MYC. In addition, p-Actin (Table 2) was amplified as a 
housekeeping gene to normalize the initial content of total cDNA. Gene 
expression in benign prostate tissue samples was calculated as the expression 
ratio compared to p-Actin. Relative hBD-1 expression was calculated by 
comparing hBD-1 expression in malignant prostate tissue, hPREC prostate 
primary culture, and prostate cancer cell lines before and after being induced for 
hBD-1 expression to the average level of hBD-1 expression in benign prostate 
tissue. In all cases, unless specified in the figure legend, the dissociation curves 
were analyzed and matched for samples used to generate data. Specifically, the 
Tm for each primer set was 77° for hBD-1 and 79° for p-Actin and cMYC. As a 
negative control, QRT-PCR reactions without cDNA template were also 
performed. All reactions were run a minimum of three times. 
Phase Contrast Microscopic Analysis 
Phase contrast microscopy was utilized to evaluate the effect of hBD-1 on 
prostate cancer cells. DU145, PC3 and LNCaP cells containing no vector, empty 
plasmid or hBD-1 plasmid were seeded onto 6-well culture plates (BD Falcon). 
The following day plasmid-containing cells were induced for a period of 48 hours 
with media containing 10 JJM Pon A, while control cells received fresh media. 
The cells were then viewed under an inverted Zeiss 1M 35 microscope (Carl 
Zeiss, Germany). Phase contrast pictures of a field of cells were obtained using 
the SPOT Insight Mosaic 4.2 camera (Diagnostic Instruments, USA). Cells were 
examined by phase contrast microscopy under 32X magnification. The digital 
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Table 2: Sequences of QRT-PCR primers. 
Sense (5'-3') Antisense (5'-3') 
p-actin 5'-CCTGGCACCCAGCACAAT-3' 5'-GCCGATCCACACGGAGTACT-3' 
hBD-1 5'-TCAGCAGTGGAGGGCAA TG-3' 5'-CCTCTGT AACAGGTGCCTTGAA T -3' 
c-MYC 5'-ACAGCAAACCTCCTCACAGCC-3' 5'-TGGAGACGTGGCACCTCTTG-3' 
GAPDH 5'-CCACCCATGGCAAA TTCCATGGCA-3' 5'-TCTAGACGGCAGGTCAGGTCAACC-3' 
AKT 5'-TCAGCCCTGGACTACCTGCA-3' 5'-GAGGTCCCGGTACACCACGT-3' 
BAD 5'-CTCAGGCCTATGCAAAAAGAGGA-3' 5'-GCCCTCCCTCCAAAGGAGAC-3' 
BID 5'-AACCTACGCACCTACGTGAGGAG-3' 5'-CGTTCAGTCCATCCCA TTTCTG-3' 
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images collected were stored as uncompressed TIFF files and exported into 
Photoshop CS software (Adobe Systems) for image processing and hard copy 
presentation. 
MTT Cell Viability Assay 
To examine the effects of hBD-1 on cell growth, we performed metabolic 
3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. 
DU145, LNCaP, PC3 and PC3/AR+ cells co-transfected with pvgRXR plasmid 
and pIND/hBD-1 construct or control pvgRXR plasmid were seeded onto a 96-
well plate at 1-5 x103 cells per well. Twenty-four hours after seeding, fresh 
growth medium was added containing 10 JJM Pon A daily to induce hBD-1 
expression for 24, 48 and 72 hours after which the MTT assay was performed 
according to the manufacturer's instructions (Promega). Reactions were 
performed three times in triplicate. 
Analysis of Membrane Integrity 
Acridine orange (AO)/ethidium bromide (EtBr) dual staining was 
performed to identify changes in cell membrane integrity, as well as apoptotic 
cells by staining the condensed chromatin. AO stains viable cells and early 
apoptotic cells, whereas EtBr stains late stage apoptotic cells that have 
compromised membranes. Briefly, PC3, DU145 and LNCaP cells were seeded 
into 2-chamber culture slides (BO Falcon). Cells transfected with empty plasmid 
or hBD-1 plasmid were induced for 24 or 48 hours with media containing 10 tJM 
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Pon A, while control cells received fresh growth media at each time point. After 
induction, cells were washed once with PBS and stained with 2 ml of a mixture 
(1:1) of AO (Sigma, St. Louis, MO) and EtBr (Promega) (5 ~g/ml) solution for 5 
min and were again washed with PBS. 
Fluorescence was viewed by a Zeiss LSM 5 Pascal Vario 2 Laser 
Scanning Confocal Microscope (Carl Zeiss). The excitation color wheel contains 
BS505-530 (green) and LP560 (red) filter blocks which allowed for the separation 
of emitted green light from AO into the green channel and red light from EtBr into 
the red channel. The laser power output and gain control settings within each 
individual experiment were identical between control and hBD-1 induced cells. 
The excitation was provided by a Kr/Ar mixed gas laser at wavelengths of 543 
nm for AO and 488 nm for EtBr. Slides were analyzed under 40x magnification 
and the images were collected and processed as previously mentioned. 
Flow Cytometry 
PC3 and DU145 cells transfected with the hBD-1 expression system were 
grown in 60-mm dishes and induced for 12,24, and 48 hours with 10 ~M Pon A. 
Following each incubation period, the medium was collected from the plates (to 
retain any detached cells) and combined with PBS used to wash the plates. The 
remaining attached cells were harvested by trypsinization and combined with the 
detached cells and PBS. The cells were then pelleted at 4° C (500 x g) for 5 min, 
washed twice in PBS, and resuspended in 100 ~I of 1xAnnexin binding buffer 
(0.1 M Hepes/NaOH at pH 7.4, 1.4 M NaCI, 25 mM CaCb) containing 5 ~I of 
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Annexin V-FITC and 5 IJI of PI. The cells were incubated at RT for 15 m in in the 
dark, then diluted with 400 IJI of 1 x Annexin binding buffer and analyzed by 
FACscan (Becton Dickinson, San Jose, CAl. All reactions were performed three 
times. 
Caspase Detection 
Detection of caspase activity in the prostate cancer cell lines was 
performed using APO LOGIX™ Carboxyfluorescin Caspase detection kit (Cell 
Technology, Mountain View, CAl. Active caspases were detected through the 
use of carboxyfluorescein labeled peptide fluoromethyl ketone (FAM-VAD-FMK) 
that irreversibly binds to active caspases. Briefly, DU145 and LNCaP cells (1.5-3 
X10
5
) containing the hBD-1 expression system were plated in 35 mm glass 
bottom dishes (Matek, Ashland, MA) and treated for 24 hours with media only or 
with media containing 10 IJM Pon A as previously described. Next, 10 IJI of a 
30X working dilution of FAM-VAD-FMK was added to 300 IJI of media and added 
to each 35 mm dish. Cells were then incubated for 1 hour at 37° C under 50/0 
CO
2
. The medium was aspirated and the cells were washed twice with 2 ml of a 
1x working dilution Wash Buffer. Cells were viewed under differential 
interference contrast (OIC) or under laser excitation at 488 nm. The fluorescent 
signal was analyzed using a confocal microscope (Zeiss LSM 5 Pascal) and a 
63x DIG oil lens with a Vario 2 RGB Laser Scanning Module. 
50 
Statistical Analysis 
Statistical analysis was performed by using the Student's t-test for 
unpaired values. P values were determined by a two-sided calculation, and a P 
value of less than 0.05 was considered statistically significant. Statistical 
differences are indicated by asterisks. 
RESULTS 
hBO-1 Expression in Prostate Tissue 
We previously demonstrated that 820/0 of prostate cancer frozen tissue 
sections analyzed exhibited little or no expression of hBD-1 136. In addition, in 
that study we observed a potential correlation between clinical prostate samples 
with little or no expression of hBD-1 and higher rates of cancer recurrence 
(unpublished data). To compare hBO-1 expression levels, QRT-peR analysis 
was performed on normal prostate tissue obtained by gross dissection or LCM of 
normal prostate tissue adjacent to malignant regions which were randomly 
chosen. Here, hBD-1 was detected in all of the gross dissected normal clinical 
samples with range of expression that represents approximately a 6.6-fold 
difference in expression level (Figure 3-1A). LCM captured normal samples 
expressed hBD-1 at levels in a range that represents a 32-fold difference in 
expression (Figure 3-1 B). Matching sample numbers to corresponding patient 
profiles revealed that in most cases, the hBD-1 expression levels was higher in 
patient samples with a Gleason score of 6 than in patient samples that had a 
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Figure 3-1: Analysis of hBD-1 expression in human prostate tissue. hBD-1 
relative expression levels were compared in normal clinical samples from 
patients that underwent radical prostatectomies. The dashed line serves as a 
point of reference to compare values obtained between gross and LCM-derived 
specimen, and corresponding Gleason scores are indicated above each bar. (A) 
hBD-1 expression levels were compared in tissues obtained by gross dissection. 
(8) hBD-1 expression levels were compared in tissue obtained by Laser Capture 
Microdissection. 
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Figure 3-1: Analysis of hBD-1 expression in human prostate tissue. 
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Gleason score of 7. In addition, a comparison of hBD-1 expression levels in 
tissue obtained by gross dissection and LCM for the same patient, #1343, 
demonstrated an 854-fold difference in expression between the two isolation 
techniques. Therefore, our results indicate LCM is a more sensitive technique to 
assess hBD-1 expression in prostate tissue. 
Transfection Efficiency in Prosate Cancer Cell Lines 
To determine the transfection efficiency, the prostate cancer cell lines 
were transfected with a GFP vector and fluorescence was monitored. 
Microscopic analysis revealed green fluorescence in only the prostate cancer cell 
lines transfected with GFP (Figure 3-2). In addition, the flow analysis of GFP 
positive cells demonstrated an approximate 50% transfection efficiency in all 
three prostate cancer cell lines. 
hBO-1 Expression in Prostate Cell Lines 
To verify upregulation of hBD-1 in the prostate cancer cell lines after 
transfection with the hBD-1 expression system, QRT -PCR was performed. In 
addition, no template negative controls were also performed, and amplification 
products were verified by gel electrophoresis (Figure 3-3). Here, hBD-1 
expression was significantly lower in the prostate cancer cell lines compared to 
hPrEC cells. Following a 24 hour induction period, relative expression levels of 
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Figure 3-2: Analysis of Transfection Efficiency with GFP Plasmid. (A) 
Microscopic analysis of GFP transfection efficiency. (8) Graph representing the 
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Figure 3-2: Analysis of Transfection Efficiency with GFP Plasmid. 
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Figure 3-3: Analysis of peR products. (A) RT-PCR was performed in DU145 
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Figure 3-3: Analysis of peR products. 
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Figure 3-4: Analysis of hBD-1 expression in prostate cell lines. hBD-1 
expression levels were compared relative to hPrEC cells in prostate cancer cell 
lines before and after hBD-1 induction. An asterisk represents statistically higher 
expression levels compared to hPrEC. Double asterisks represent statistically 
significant levels of expression compared to the cell line before hBD-1 induction 
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Figure 3-4: Analysis of hBD-1 expression in prostate cell lines. 
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hBO-1 significantly increased in DU145, PC3 and LNCaP as compared to the cell 
line prior to hBD-1 induction (Figure 3-4). Analysis of hBD-1 relative expression 
in the prostate cancer cell lines revealed that we can induce hBD-1 in prostate 
cancer cells as compared to endogenous hBD-1 expression in normal prostate 
cells. 
Next, we verified protein expression of hBD-1 in DU145 cells transfected 
with the hBD-1 expression system after induction with Pon A utilizing 
immunocytochemistry. As a positive control, hBD-1 expressing hPrEC prostate 
epithelial cells were also examined. Cells were stained with primary antibody 
against hBD-1 and protein expression was monitored based on the green 
fluorescence of the secondary antibody (Figure 3-5). Analysis of cells under DIG 
verifies the presence of hPrEC cells and DU 145 cells at 18 hours. Excitation by 
the confocal laser at 488 nm revealed green fluorescence indicating the 
presence of hBD-1 protein in hPrEC. However, there was no detectable green 
fluorescence in control DU145 and pvgRXR induced DU145 cells demonstrating 
no hBD-1 expression (d and f, respectively). Confocal analysis of DU145 (h) 
cells induced for hBD-1 expression revealed green fluorescence indicating the 
presence of hBD-1 protein following induction with Pon A. 
Expression of hBD-1 Results in Decreased Cell Number and Viability 
To test the effect of hBD-1 on prostate cancer cell lines, we perfonned 
phase contrast microscopic analysis of prostate cancer cell lines. Induction of 
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Figure 3·5: Analysis of hBO-1 protein expression. Ectopic hBD-1 expression 
was verified in the prostate cancer cell line DU145 by immunocytochemistry. 
hPrEC cells were stained for hBD-1 as a positive control (a: DIG and b: 
fluorescence). DU145 control cells (c: DIG and d: fluorescence) or DU145 cells 
transfected with pvgRXR alone (e: DIG and f: fluorescence) or hBD-1 and 









Figure 3-5: Analysis of hBD-1 protein expression. 
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hBD-1 in the prostate cancer cell lines resulted in a significant reduction in cell 
number in DU145 and PC3, but had no effect on cell proliferation in LNCaP 
(Figure 3-5). As a negative control, cell growth was monitored in all three lines 
after the induction of the pvgRXR vector. There were no observable changes in 
cell number in DU145, PC3 or LNCaP cells. 
We performed an MTT assay to assess the effect of hBD-1 expression on 
relative cell viability in DU145, PC3, PC3/AR+ and LNCaP prostate cancer cell 
lines. MTT analysis with pvgRXR vector exhibited no statistically significant 
change in cell viability (data not shown). Twenty-four hours following hBD-1 
induction, relative cell viability was 72% in DU145 and 56% in PC3, and after 48 
hours cell viability was reduced to 49% in DU145 and 370/0 in PC3 (Figure 3-7). 
Following 72 hours of hBD-1 induction, relative cell viability decreased to 44% in 
DU145 and 29% PC3 cells. Conversely, there was no significant effect on the 
viability of LNCaP cells. In order to assess whether the resistance to hBD-1 
cytotoxicity observed in LNCaP was due to the presence of the androgen 
receptor (AR), we examined the hBD-1 cytotoxicity in PC3 cells with ecpotic AR 
expression (PC3/AR+). Here, there was no difference between PC3/AR+ and 
PC3 cells. Therefore, the data suggest that hBD-1 is cytotoxic specifically to 
late-stage prostate cancer cells. 
In order to determine whether the effects of hBD-1 on PC3 and DU145 
were cytostatic or cytotoxic, FACS analysis was performed to measure cell 
death. Under normal growth conditions, more than 90% of PC3 and DU145 
cultures were viable and non-apoptotic (lower left quadrant) that did not stain with 
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Figure 3·6: Analysis of hBO-1 on prostate cancer cells. Cell number in 
DU145, PC3 and LNCaP was monitored by phase contrast microscopy after 48 
hours of hBD-1 induction. Size bar= 20 IJM. 




Figure 3-6: Analysis of hBO-1 on prostate cancer cells. 
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Figure 3-7: Analysis of hBD-1 effect on cell viability. The prostate cell lines 
DU145, PC3, PC3/AR+ and LNCaP were treated with Pon A to induce hBD-1 
expression for 1-3 days after which MTT assay was performed to determine cell 
viability. Each bar represents the mean + S.E.M. of three independent 
experiments performed in triplicate. 
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Figure 3-7: Analysis of hBD-1 effect on cell viability. 
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annexin V or PI (Figure 3-8). After inducing hBD-1 expression in PC3 cells, the 
number of cells undergoing early apoptosis and late apoptosis/necrosis (lower 
and upper right quadrants, respectively) totaled 10% at 12 hours, 200/0 at 24 
hours, and 44% at 48 hours. For DU145 cells, the number of cells undergoing 
early apoptosis and late apoptosis/necrosis totaled 12% after 12 hours, 34% at 
24 hours, and 59% after 48 hours of induction. No increase in apoptosis was 
observed in cells containing empty plasmid following induction with Pon A (data 
not shown). Annexin V and propidium iodide uptake studies have demonstrated 
that hBD-1 has cytotoxic activity against DU145 and PC3 prostate cancer cells 
and results indicate apoptosis as a mechanism of cell death. 
hBO-1 Causes Alterations in Membrane Integrity and Caspase Activation 
We investigated whether the cell death observed in prostate cancer cells 
after hBD-1 induction is caspase-mediated apoptosis. To better understand the 
cellular mechanisms involved in hBD-1 expression, confocal laser microscopic 
analysis was performed (Figure 3-9) on DU145, PC3, and LNCaP cells induced 
for hBD-1 expression. Pan-caspase activation was monitored based on the 
binding and cleavage of green fluorescing FAM-VAO-FMK to caspases in cells 
actively undergoing apoptosis. Analysis of cells under DIC showed the presence 
of viable control DU145 (a), PC3 (e), and LNCaP (i) cells at 0 hours. Excitation 
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Figure 3-8: Analysis of hBD-1 cytotoxicity in prostate cancer cells. Cells 
positive for propidium iodide and annexin V were considered apoptotic. Times of 
induction are shown under each panel. Numbers next to the boxes for each time 
point represent the percentages of propidium iodide (PI)- annexin V+ cells (lower 
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Figure 3-8: Analysis of hBD-1 cytotoxicity in prostate cancer cells. 
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Figure 3-9: Analysis of pan-caspase activation. Analysis of hBD-1 mediated 
cell death in OU145, PC3, and LNCaP prostate cancer cells. OIC visualization of 
cells before (a, e, and I, respectively) and after (c, g, and k, respectively) hBO-1 
induction. Fluorescence analysis revealed no caspase activity in control cells (b, 
f, and j, respectively), however, cells treated with Pon A for 24 h to induce hBO-1 
revealed caspase activity in DU145 and PC3 (d and h respectively), but not in 
LNCaP (I). 
Conttol 1nd.1I£ed 




Figure 3-9: Analysis of pan-caspase activation. 
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by the confocal laser at 488 nm produced no detectable green staining which 
suggests no caspase activity in DU145 (b), PC3 (f), or LNCaP (j) control cells. 
Following induction for 24 hours, DU145 (c.), PC3 (g.), and LNCaP (h.) 
cells were again visible under DIG. Confocal analysis under fluorescence 
revealed green staining in DU145 (d.) and PC3 (h.) cells indicating pan-caspase 
activity after the induction of hBD-1 expression. However, there was no green 
staining in LNCaP (I.) cells induced for hBD-1 expression. Therefore, cell death 
observed following induction of hBD-1 is caspase-mediated apoptosis. 
The proposed mechanism of antimicrobial activity of defensin peptides is 
the disruption of the microbial membrane due to pore formation 33,64. In order to 
determine if hBD-1 expression altered membrane integrity EtBr uptake was 
examined by confocal analysis (Figure 3-10). Intact cells were stained green due 
to AD which is membrane permeable, while only cells with compromised plasma 
membranes stained red due to incorporation of membrane impenneable EtBr. 
Control DU145 and PC3 cells stained positively with AD and emitted green color, 
but did not stain with EtBr. Howev~r, hBD-1 induction in both DU145 and PC3 
resulted in the accumulation of EtBr in the cytoplasm at 24 hours as indicated by 
the red staining. By 48 hours, DU145 and PC3 possessed condensed nuclei and 
appeared yellow due to the co-localization of green and red staining from AO and 
EtBr, respectively. Conversely, there were no observable alterations to 
membrane integrity in LNCaP cells after 48 hours of induction as indicated by 
positive green fluorescence with AD, but lack of red EtBr fluorescence. This ... ~ 
finding suggests that alterations to membrane integrity and permeabilization in 
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Figure 3-10: Analysis of membrane integrity. Membrane integrity of DU145, 
PC3 and LNCaP was analyzed by confocal microscopy 24 and 48 h after hBD-1 
induction. Green staining indicates the localization of AD, red staining represents 
EtBr and yellow staining represents the co-localization of both AO and EtBr. Size 
bars = 10 pM. 




Figure 3-10: Analysis of membrane integrity. 
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response to hBO-1 expression differ between early- and late-stage prostate 
cancer cells. 
hBD-1 Expression Correlates with cMYC and PAX2 
QRT-peR analysis was performed on LCM prostate tissue sections from 
three patients. Here, hBD-1 expression exhibited a 2.7-fold decrease from 
normal to PIN, a 3.5-fold decrease from PIN to tumor and a 9.3-fold decrease 
from normal to tumor in patient # 1457 (Figure 3-11). Likewise, we observed 
cMYC expression followed a similar expression pattern in patient # 1457 where 
expression decreased by 1.7-fold from normal to PIN, 1.7-fold from PIN to tumor 
and 2.8-fold from normal to tumor. In addition, we saw a statistically significant 
decrease in cMYC expression in the other two patients. Patient # 1569 had a 
2.3-fold decrease from normal to PIN, while in patient # 1586 we saw a 1.8-fold 
decrease from normal to PIN, a 4.3-fold decrease from PIN to tumor and a 7.9-
fold decrease from normal to tumor. Conversely, PAX2 expression increased 
from normal to malignant tissue by 6.6-fold in patient # 1586. Although we did 
not observe a direct correlation of hBD-1 and PAX2 expression, our results 
indicate that both PAX2 and cMYC expression may influence hBO-1 levels. 
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Figure 3-11: QRT-peR analysis of hBD-1 and cMYC expression in LCM 
human prostate tissue sections of normal, PIN, and tumor .. Expression for 
each gene is presented as expression ratios compared to p-actin. (A) 
Comparison of hBO-1 expression levels in normal, PIN and tumor sections. (8) 
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Figure 3-11: QRT -PCR analysis of hBD-1 and cMYC expression in LCM 
human prostate tissue sections of normal, PIN, and tumor. 
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Induction of hBO-1 Expression Following PAX2 Inhibition 
To further examine the role of PAX2 in regulating hBD-1 expression, we 
utilized siRNA to knockdown PAX2 expression and performed QRT-peR to 
monitor hBD-1 expression. Treatment of hPrEC cells with PAX2 siRNA exhibited 
no effect on hBD-1 expression (Figure 3-12). However, PAX2 knockdown 
resulted in a 42-fold increase in LNCaP, a 37-fold increase in PC3 and a 1026-
fold increase in DU145 expression of hBD-1. As a negative control, cells were 
treated with non-specific siRNA which had no significant effect on hBD-1 
expression (data not shown). 
DISCUSSION 
The identification of susceptibility genes and genetic alterations 
associated with prostate cancer has greatly enhanced our understanding of the 
disease 65. However, the basic mechanism underlying prostate carcinogenesis is 
still poorly understood. Recent interest has focused on the role inflammation or 
infection in the progression of prostate cancer 65-67. Members of the defensin 
family of peptides have an important role in host defense against bacterial j fungal 
and viral infections 68 and are considered a critical part of the initial response to a 
pathogen 35. In contrast to other members of the defensin family, hBD-1 exhibits 
no activity against fungal and viral infections and only very weak antimicrobial 
activity. Given this, the exact role of hBD-1 expression in the epithelial cell 
remains unclear 69-71. 
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Figure 3-12: QRT-PCR analysis of hBD1 expression following PAX2 
knockdown with siRNA. hBO-1 expression levels are presented as expression 
ratios compared to p-actin. An asterisk represents statistically higher expression 
levels compared to the cell line before PAX2 siRNA treatment (Student's t-test, 
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Figure 3-12: QRT-PCR analysis of hBD1 expression following PAX2 
knockdown with siRNA. 
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Our previous studies have shown that hBD-1 expression is lost at a high 
frequency in prostate cancer2°. However, little is known about its function in 
cancer or whether the loss of expression contributes to prostate tumor 
progression. There has been increasing interest in whether host defense 
peptides possess anti-cancer activity137. Here we show that hBO-1 is cytotoxic to 
prostate cancer cells. Overall, hBD-1 expression was 10- to almost 1 ODD-fold 
less in grossly dissected tissues compared to LCM tissue samples. Furthermore, 
expression in benign prostate tissue adjacent to cancer varied over a range 
differing by 6.6-fold difference in gross dissected tissues and a 32-fold difference 
in LCM derived tissue. In this, we found that patient #1343 had an 854-fold 
difference in detectable hBD-1 expression when comparing gross and LCM 
derived tissue. The increase in detectable levels of hBD-1 from gross to LCM 
derived tissue indicates LCM is a more sensitive technique to analyze expression 
of hBO-1. Additionally analysis indicated that in most cases, patient samples 
with higher hBD-1 expression levels had a Gleason score of 6, while those with 
less expression were diagnosed with cancers having Gleason score of 7. 
Although LCM derived tissue appeared to display the trend of higher hBD-1 
expression and lower Gleason score, other factors such as degree of 
inflammation within the tissue were not evaluated in this study. In addition, we 
have preliminary data from a previous long-term patient follow-up which suggests 
that those with little to no hBD1 expression experienced higher cancer 
recurrence rates compared to those with higher expression levels. Taken 
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together, these results suggest that decreased or loss of hBD-1 expression and 
its subsequent anti-cancer activity may contribute to prostate tumor progression. 
In 2006, Sherman et al. published data indicating that hBD-1 is 
upregulated in response to BSA treatment and the pathway involved may be 
regulated by the c-Myc proto-oncogene137, 138. C-myc has also been shown to 
sensitize tumor cells to various apoptotic stimuli139 . One of these pathways 
involves the permeabilization of the cellular and mitochondrial membranes, and 
the release of cytochrome C. Therefore, c-Myc must act to potentiate the ability 
of an additional factor to induce permeabilization and cytochrome C release. 
However, in cancer cells c-Myc-induced release of cytochrome C is suppressed 
by cell survival factors, which subsequently exacerbates c-Myc oncogenicity. 
Given that all potential pro-apoptotic actions of c-Myc involve its 
functional integrity as a transcription factor, it is possible that c-Myc modulates 
target genes that encode proteins which can permeabilize the mitochondrial 
membrane. Here we show that hBD-1 causes rapid cell death in late-stage 
prostate cancer cells via the disruption of cell membrane potential and caspase 
activation. Furthermore, we found!"a positive correlation between cMyc and hBO-
1 in one of three prostate tissue samples, where tissue exhibiting decreased 
cMyc expression also possessed a decreased hBO-1 level. This suggests that 
the loss of hBD1 observed in prostate cancer may be due to the down-regulation 
of cMyc expression or by the up-regulation of transcription factors acting as pro-
survival factors, therefore preventing the triggering of apoptosis, and ultimately 
promoting tumor progression. 
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Paired box 2, PAX2, is a member of the PAX gene family of transcriptional 
regulators that functions early in the development of the urogenital system 140. 
Although PAX2 is typically repressed upon terminal differentiation, in urogenital 
cancers including prostate cancer it has been shown to be overexpressed141 , 142. 
In addition, studies have demonstrated that PAX2 expression can stimulate 
proliferation stimulus, thus serving as a critical component of a multi-step 
oncogenic transformation process 143. Therefore, PAX2 may offer an advantage 
for the survival and growth of cancer cells. 
PAX genes function to activate or repress transcription by transactivating 
the promoters of target genes that regulate cell growth and apoptosis 144. Unique 
recognition sequences are contained within the paired domain and activating 
domains in PAX2 that aid to activate or repress the transcription of specific 
genes145, 146. Examination of the hBD-1 promoter revealed a PAX2 recognition 
sequence between bases-172 and -157 upstream of the TAT A box (data not 
shown). Here we demonstrate a 6.6-fold increase from normal to tumor in PAX2 
expression in patient # 1586. Although we did not observe a direct correlation 
with hBD-1 and PAX2 expression in the patient samples tested, we did 
demonstrate that suppression of PAX2 protein expression by siRNA results in the 
re-expression of hBD1. These findings suggest that PAX2 is a transcriptional 
repressor of hBD-1 expression although this was not examined in this study. 
Taken together, it is plausible that the delicate balance of the regulation of hBD-1 
expression may playa key role in determining the fate of cancer cells and tumor 
progression. 
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In summary, data presented here demonstrate that hBO-1 expression is 
highly cytotoxic to DU145 and PC3 which represent AR negative, hormone 
refractory late-stage prostate cancer. These findings suggest that hBO-1 has 
anti-cancer and/or tumor suppressive activities and that its suppression or loss 
contributes to cancer cell survival and tumor progression. Cytotoxic effects of 
hBO-1 observed in DU145 and PC3, but not in LNCaP suggest that hBO-1 
specifically affects late-stage prostate cancer cells. This reasoning is further 
supported by the high frequency of cancer-specific loss of hBD-1 expression, and 
that hBD-1 loss of expression may influence Gleason grading and cancer 
recurrence. Therefore, hBD-1 may be an integral component of the innate 
immune system involved in the recognition and destruction of cancer cells. In 
conclusion, our studies are the first to demonstrate hBO-1 functionality in 
prostate cancer progression, thus offering hBO-1 as a viable therapeutic agent 
for the treatment of late-stage prostate cancer. 
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CHAPTER 4 
CELLULAR MECHANISMS ASSOCIATED WITH THE 





Apoptosis is a mechanistic process whereby the activation of cysteine-
aspartate proteases (caspases) results in programmed cell death that allows 
multicellular organisms to regulate cell number within tissues. It is characterized 
by stereotypical morphological changes, such as chromatin condensation and 
fragmentation, cell shrinkage, and alterations of the plasma membrane. In part, 
apoptosis is regulated by the Bcl-2 fam ily of proteins 147. There are two pathways 
of apoptosis, an extrinsic pathway involving ligand activated cell death receptors 
and an intrinsic pathway involving mitochondrial alterations initiated by a variety 
of stress signals 141. The extrinsic pathway involves the recruitment of adapter 
proteins that lead to the activation of caspase 8 and the initiation of the caspase 
cascade. Activated caspase 8 catalyzes the cleavage of BID leading to the 
translocation of tBID to the mitochondria and subsequent cell death. In the 
intrinsic pathway, the release of cytochrome c from the mitochondria, in 
conjunction with APAF-1, results in the formation of the apoptosome. This aids 
in the cleavage of procaspase-9 inJhe presence of ATP generating an active 
caspase 9, which, in turn, activates the effector caspases. The extrinsic and 
intrinsic pathways merge at caspase 3 activation to complete the apoptotic 
process. Ultimately, the process results in the morphological and biochemical 
changes characteristic of apoptotic death. 
Apoptosis is an important and physiologically normal course of action for 
multicellular organisms148 . It is accepted that th~_growth and progression of a 
tumor is regulated by deregulation of the balance between proliferation and 
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apoptosis 149,150. The ability of a cell to evade apoptosis is an important 
characteristic that defines the transition from a normal cell to malignant151 . 
Further study into the molecular mechanisms underlying the process could lead 
to the development of possible preventative strategies. 
In prostate cancer, mortality is a consequence of metastasis to the lymph 
nodes and bone, as well as a progression from androgen-dependent to 
androgen-independent growth 152. There are limited treatment options beyond 
localized prostate cancer due to the ineffective nature of chemotherapy to 
increase patient survival in metastatic prostate cancer153. Although the 
accumulation of genetic alterations and environmental insults contributes to the 
development and progression of prostate cancer, the exact molecular 
mechanisms underlying these processes are unknown. An important 
pathophysiological response that appears to contribute to prostate cancer 
involves the inhibition of apoptosis. Therefore, identification of potential 
therapeutic targets that manipulate the apoptotic process may serve as 
alternative treatment methods leading to a decrease in prostate cancer mortality 
rates. 
MATERIALS AND METHODS 
Specific Caspase Activity 
Specific caspase activity in the prostate cancer cell lines was detected 
using the Carboxyfluorescein or Sulforhodamine FLICA Apoptosis Detection Kit 
Caspase Assay (Immunochemistry Technologies~-·LLC, Bloomington, MN). 
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Caspase 8 was detected with a FAM-LETO-FMK peptide, caspase 9 with a FAM-
LEHO-FMK peptide, and caspases 3 & 7 with a SR-OEVO-FMK peptide that 
irreversibly binds to active caspases. Briefly, 1.5-3x1 05 DU 145, LNCaP and PC3 
cells were plated on 35-mm glass bottom dishes (MATEK, Ashland, MA) and 
were transfected with the hBD-1 expression system. As previously described, 
cells were exposed to media only or media containing Pon A for 24-48 hours. 
Next, 10 ul of a 30X working dilution of the appropriate fluoromethyl ketone 
labeled peptide was added to 300 ul of media and incubated with each 35-mm 
dish for 1 hour at 37°e under 5% CO2 _ Then, the medium was aspirated and the 
cells were washed twice with 2 ml of 1X working dilution Wash buffer. Cells were 
viewed under differential interference contrast (Ole) or laser excitation at 488 
nm. The fluorescent signal and DIC images were analyzed using a confocal 
microscope (Zeiss LSM 5 Pascal) and 63X oil lens with a Vario 2 RGB Laser 
Scanning Module. Images were collected and processed as previously 
mentioned. 
RNA Isolation and Quantitative RT-PCR 
QRT -peR was performed as previously described135. Briefly, total RNA 
(O.5 1-19 per reaction) from both sources was reverse transcribed into eDNA 
utilizing random primers (Promega). Two-step QRT -peR was performed on 
eDNA generated using the MultiScribe Reverse Transcriptase from the TaqMan 
Reverse Transcription System and the SYBR Green peR Master Mix (Applied 
Biosystems, Foster City, CA). The primer pairs for AKT, BAD, and BID were 
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designed from the published sequences (Table 2). Forty cycles of peR were 
performed under standard conditions using an annealing temperature of 58° C. 
In addition, GAPDH (Table 2) was amplified as a housekeeping gene to 
normalize the initial content of total cDNA. Gene expression in benign prostate 
tissue samples was calculated as the expression ratio compared to GAPDH. 
Relative expression was calculated by comparing mRNA levels in prostate 
cancer cell lines after being induced for hBD-1 expression to the level of mRNA 
expression in control cells. In all cases, the dissociation curves were analyzed 
and matched for samples used to generate data. As a negative control, QRT-
peR reactions without cDNA template were also performed. All reactions were 
run a minimum of three times. 
Western Blot Analysis 
Protein levels were analyzed by western blot analysis. Briefly, 5-7.5 x105 
cells were plated on 100mm dishes and transfected with the appropriate amount 
of pvgRXR vector or pIND/hBD-1 plasmid. Lysates were collected following 20h 
of induction with Pan A. Samples were prepared for a triple load: 75 pi sample, 
15 pi sample buffer, and 1.5 pl1 M OTT. After incubation at 70 0 e for 10 min, the 
samples were loaded onto a 4-12% NuPAGE gel and run for 50 min at 200V with 
MES running buffer containing anti-oxidant (Invitrogen). Transfer was perfonned 
at 30V for 1 hr (one gel/power supply) or 1.5 hrs (two gels/power supply). The 
nitrocellulose was blocked in 5% milk in T8S-T for a minimum of 30 min at RT. 
Incubation O/N at 4°C in 5% milkrrBS-T with a primary antibody concentration of 
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1:1000 for anti-caspase 3, anti-caspase 8, anti-caspase 9, Bid, Bad, AKT, pAKT, 
and p-actin (Cell Signaling, Beverly, MA) was followed with 3x10 min washes 
with TBS-T. Then, the blots were incubated for 1-2 hrs at RT in 5% milk-TBS-T 
with secondary antibody (1 :5000 mouse, 1 :50000 rabbit), washed 3x10 min T8S-
T and incubated with chemiluminescent reagent prior to development. 
RESULTS 
hBD-1 Causes Caspase Activation 
We have shown that the induction of hBD-1 expression in DU145 and PC3 
prostate cancer cell lines results in the activation of caspases, while there are no 
active caspases observed in LNCaP. To better understand the molecular 
mechanisms involved in caspase-mediated cell death, confocal microscopic 
analysis was performed. In order to delineate the apoptotic response in cells 
induced for hBO-1 expression, caspase 8 from the extrinsic pathway, caspase 9 
for the intrinsic pathway and caspase 3 where the two pathways converge were 
monitored with a FAM-FLICA or SR-FLICA kit that reacts with the active caspase 
within minutes. 
Analysis of caspase 8 activation with FAM-LETO-FMK, a fluorescent 
green probe, demonstrated no detectable staining in DU145, PC3 or LNCaP 
control cells (Figure4-1). However, confocal analysis of DU145 and PC3 cells 
induced for hBO-1 expression revealed green staining indicative of caspase 8 
activation. Similarly, specific activation of caspase 9 was monitored with FAM-
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Figure 4-1: Analysis of caspase 8 activation. Fluorescence analysis revealed 
no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase 
8 activation was observed in DU145 and PC3 induced for hBD-1 expression. 
DU145 PC3 LNCaP 
Control 
Induced 
Figure 4-1: Analysis of caspase 8 activation. 
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LEHD-FMK, a green fluorescent probe. Again, the analysis of control cells 
produced no detectable green fluorescence, while DU145 and PC3 cells induced 
for hBD-1 expression revealed the green fluorescence indicating the presence of 
active caspase 9 (Figure 4-2). The activation of caspase 3 was monitored with 
SR-DEVD-FMK, a fluorescent red probe, in DU145, PC3 and LNCaP prostate 
cancer cell lines. There was no detectable staining in control cells, however, red 
fluorescence was observed in DU145 and pe3 cells following induction for the 
expression of hBD-1 (Figure 4-3). Therefore, the cell death observed following 
induction of hBD-1 is caspase-mediated apoptosis which involves both the 
intrinsic and extrinsic pathways converging at caspase 3, the effector caspase. 
To verify the fluorescence data, we monitored the protein levels of 
caspases 3,8, and 9 in DU145 cells before and after induction. Cells induced for 
the expression of the pvgRXR vector or hBD-1 plasm id for 24hrs were analyzed 
by western blot (Figure 4-4). There was not a significant decrease from control in 
the cells induced for pvgRXR in procaspases 3, 8, and 9. However, a reduction 
in procaspases 3, 8, and 9 was observed in cells induced for hBD-1 expression. 
Additionally, the fragments that result from the cleavage of procaspase 3 and 9 
into the active forms were shown. ImageJ analysis verified the decrease in 
procaspase 3,8, and 9 levels observed by western blot (data not shown). 
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Figure 4 ... 2: Analysis of caspase 9 activation. Fluorescence analysis revealed 
no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase 
9 activation was observed in DU145 and PC3 induced for hBD-1 expression. 
DU145 pe3 LNCaP 
Control 
Induced 
Figure 4-2: Analysis of caspase 9 activation. 
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Figure 4-3: Analysis of caspase 3 activation. Fluorescence analysis revealed 
no caspase activation in DU145, PC3, or LNCaP control cells. However, caspase 
3 activation was observed in DU145 and PC3 induced for hBO-1 expression. 
DU145 PC3 LNCaP 
Control 
Induced 
Figure 4-3: Analysis of caspase 3 activation. 
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Figure 4-4: Western blot analysis of caspase activation. Protein from DU145 
cells was collected to perform a western blot analysis following induction for hBO-
1 expression. 
Control pvgRXR hBD-1 
Procaspase 3 





Figure 4-4: Western blot analysis of caspase activation. 
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Regulators of Apoptosis following hBD-1 expression 
Several regulators of apoptosis are important to the activation or 
suppression of cell death. Akt, an important pro-survival kinase, is involved in 
protecting cells from apoptosis. Stimulation with growth factors leads to Akt 
recruitment to the plasma membrane and phosphorylation at two key regulatory 
sites, Thr308 and Ser473 , by 3-phosphoinositide-dependent protein kinase-1 
(PDK1 )154. Analysis of the effect of hBD-1 expression on Akt mRNA levels 
revealed a decrease in DU145 and no change in PC3, while protein analysis in 
DU145 demonstrated no change in Akt levels and a slight decrease in pAkt 
(Figure 4-5). 
One important substrate of Akt is Bad, a BH3-domain protein which if 
phosphorylated becomes sequestered to the cytoplasm and prevents it from 
translocating to the mitochondrion where it exerts its pro-apoptotic action 155. An 
increase in Bad mRNA levels was observed in both DU145 and PC3 following 
the induction of hBD-1 (Figure 4-6). Subsequent analysis of Bad protein levels 
demonstrated a decrease in hBO-1 induced cells from those of control DU145. 
At first, the observed decrease in Bad protein levels suggests that there is less 
apoptosis. However, it is important to note that the RNA and protein isolates 
were collected at the 24h time pOint. Since an increase in transcript levels was 
observed, additional later time points may have demonstrated the expected 
increase in Bad protein levels. 
The final pro-apoptotic factor that was analyzed, Bid, is cleaved by 
activated caspase 8 into a truncated BH-3 only domain form known as tBid. It 
102 
Figure 4-5: Effect of hBD-1 on Akt and pAkt expression. (A) Akt m RNA 
expression in DU145 and PC3 before and after induction for hBD-1 expression. 
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Figure 4-5: Effect of hBO-1 on AKT and pAKT expression. 
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Figure 4-6: Effect of hBD-1 on Bad expression. (A) mRNA expression in 
DU145 and pe3 before and after induction for hBD-1 expression. (8) Protein 
expression in DU145: lane 1-control cells, lane 2- cells induced for pvgRXR 
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Figure 4-7: Effect of hBD-1 on Bid expression. (A) mRNA expression in 
DU145 and PC3 before and after induction for hBD-1 expression. (8) Protein 
expression in DU145: lane 1-control cells, lane 2- cells induced for pvgRXR 
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results were evidenced by a decrease in cell number and the appearance of 
cleaved caspase 8 and 9 fragments57. Furthermore, in mice it has been shown 
the over-expression of mouse p-defensin-6 results in myofiber apoptosis 159. 
In summary, data presented here support the recent findings that 
demonstrate hBO-1 expression is highly cytotoxic in human prostate cancer cells. 
Specifically, we have shown that the death observed in DU145 and PC3 prostate 
cancer cells involves the activation of caspases 3,8 and 9. In addition, there 
were alterations in the expression pattern of various regulators of apoptosis. We 
are confidant the induced cell death is due to hBO-1 expression because 
appropriate vector controls were used in each experiment. These findings 
suggest that hBD-1 has anti-cancer activities via an apoptotic cell death. Taken 
together, it is plausible that hBO-1 expression within the tumor microenvironment 
may playa key role in determining the fate of cancer cells and tumor 
progression. However, the mechanisms and receptors, if any, involved in the 
pro-apoptotic response of hBO-1 remain unclear and require additional studies. 
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CHAPTER 5 
ROLE OF HBO-1 IN PROSTATE CANCER PROGRESSION 
111 
INTRODUCTION 
One philosophy for the successful treatment of cancer involves 
eradicating all of the tumor cells from the body. Conventional modalities to 
eliminate cancer cells include surgical removal of the tumor mass, radiotherapy 
and chemotherapy which use exposure to toxic ionizing radiation and chemicals, 
respectively, to destroy tumor cells. Although these methods are regularly used 
to treat cancer, they have associated limitations and side effects. 
There are two significant limitations connected with the use of radio- or 
chema-therapy. First, there is an observed toxicity to both malignant cells and 
their normal counterparts rapidly dividing within the treatment field. Second, 
there is significant data that shows the development of drug resistance within a 
subset of malignant cells following treatment. In an effort to circumvent these 
limitations, research has been conducted to identify new modalities without the 
side effects to the host. 
One particular area of interest involves the phenomena termed bystander 
.. 
effect. Typically, the term bystander effect is used in radiobiology to describe the 
effects of radiation on cells adjacent to those directly affected by radiation. 
However, it has recently been adapted more generally to refer to the effect a 
particular treatment of cells has on those that have not received any treatment. 
The work presented here was designed to test our hypothesis that hBD-1 
exhibits a bystander effect. In this study, we testihis hypothesis by assessing 
the effect of hBD-1 containing media on prostate cancer cell lines. Although we 
1 12 
do not observe a bystander effect in our studies, our results indicate a possible 
upward trend. This suggests that under conditions other than those used in this 
study, hBO-1 may exhibit a bystander effect. Due to the role hBD-1 has in innate 
and adaptive immunity, the restoration of expression in cancer cells where it has 
been lost may prove to be a useful antitumor therapy. 
MATERIALS AND METHODS 
MTT Cell Viability Assay 
To examine the bystander effects of hBO-1 on prostate cancer cells, we 
perfonned metabolic 3-[4,5-dimethylthiazol-2y1]-2,5-diphenyl tetrazolium brom ide 
(MTT) assay. DU145 and PC3 cells were seeded onto a 96-well plate at 5 x103 
cells per well. Twenty-four hours after seeding, fresh growth medium was added 
to control cells, while test conditions were treated with medium exposed to 
hPrEC cells for 24-48 hours. After incubation with the conditioned media for 24, 
48, and 72 hours a MTT assay was performed according to the manufacturer's 
instructions (Prom ega}. Reactions were performed three times in triplicate. 
AD/EtBr Confocal Analysis 
AO/EtBr staining was performed to identify changes in cell 
membrane integrity as described previously. Briefly, DU145 and LNCaP cells 
were seeded onto 35mm dishes. Cells transfected with pvgRXR vector or hBO-1 
plasmid were induced for 24 or 48 hours with media containing 10 fJM Pan A, 
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while control cells received fresh growth media at each time point. At the 
appropriate time point, the media was collected and placed onto DU145 and 
LNCaP cells seeded onto 2-chamber slides. The cells were incubated with the 
conditioned medium for 24 or 48 hours prior to staining. Then, cells were 
washed once with PBS and stained with 2 ml of a mixture (1:1) of AD (Sigma, St. 
Louis, MO) and EtBr (Promega) (5 Jjg/ml) solution for 5 min and were again 
washed with PBS. Fluorescence was viewed by a Zeiss LSM 5 Pascal Varia 2 
Laser Scanning Confocal Microscope (Carl Zeiss) under 40x magnification and 
the images were collected and processed as previously mentioned. 
Trypan Blue Exclusion 
DU145 and LNCaP cells were plated on 60mm dishes and transfected 
with pvgRXR vector or hBD-1 plasmid. Following induction for 24 hours with 
media containing 10 JjM Pan A or fresh growth media for control cells, the media 
was collected and place onto DU145 and LNCaP cells seeded into 6-well plates. 
After incubation with the conditioned medium for 24 hours, the cells were washed 
~ 
with PBS and collected. The cells were stained with a mixture (1:1) of cells and 
PBS containing 0.4% Trypan Blue (Invitrogen). Cells were counted after a 5 min 
incubation at RT as viable (no blue stain) or non-viable (blue stain) in four 
quadrants of a hemocytometer. Data are presented as percent non-viable as 
follows: % non-viable= # non-viable/total (viable+non-viable) x 100. Phase 
contrast pictures of the field of cells on the hemocytometer were obtained and 
~-
the images processed as previously described. 
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Hoechst Stain 
DU145, PC3 and LNCaP control cells or transfected with pvgRXR vector 
or hBD-1 plasmid were induced for 24 and 48 hours with 10 J..IM Pon A or fresh 
growth media (controls). Following each incubation period the medium was 
collected from the plates, spun briefly and placed on DU145, PC3 or LNCaP 
recipient cells. Recipient cells were exposed to the conditioned donor medium 
for 24,48, or 72 hours prior to analysis, while donor cells received new media 
containing 30pl of 1 x Hoechst 33342 dye. After 5 min of incubation, cells were 
analyzed under UV light on a Zeiss fluorescent microscope under 20x 
magnification. Images were captured and processed as previously described. 
The protocol was performed on recipient cells following the appropriate exposure 
to conditioned medium with the addition of 15pl of 1 x Hoechst 33342 dye. 
Flow Cytometry 
DU145 cells transfected with the hBD-1 expression system and control 
cells were grown in 60-mm dishes· were induced for 24 and 48 hours with 10 IJM 
Pan A or fresh growth media, respectively. The donor cells were used to 
generate conditioned media for recipient cells. Following each incubation period 
the medium was collected from the donor plates, spun briefly and placed on 
DU145 and LNCaP recipient cells. Recipient cells were exposed to the 
conditioned donor medium for 24, 48, or 72 hours prior to a wash with PBS. The 
attached donor or recipient cells were harvested-by trypsinization and pelleted at 
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4° C (1500 rpm) for 5 min, washed in PBS, and resuspended in 100 lJl PBS. 
While vortexing or bubbling with a pipette, 2 ml of 70% EtOH was added drop-
wise. Samples were stored 1 h to 3 days at 4° C. Then, the suspension was 
washed with PBS and pelleted at 4° C (3000 rpm) for 5 min. The pellet was 
resuspended in 100pl of PBS prior to the addition of 100pl RNase (Sigma, 
1mg/ml) and 200pl of propidium iodide solution (1:100 dilution of a 1mg/ml 
stock). Samples were vortexed and stored at 4° C for at least 30 min wrapped in 
foil prior to flow analysis by FACscan (Becton Dickinson). All reactions were 
performed two times. 
RESULTS 
Effect of conditioned media on cell viability 
To better understand the mechanism of action of hBD-1, it is important to 
assay whether the peptide acts in an autocrine or paracrine manner. It is widely 
accepted that hBD-1 is constitutively expressed by epithelial cell S90 , Several 
groups have reported the secretion of hBD-1 peptide into the media of human 
epithelial cell lines including gastrio (AGS)160, colon (HT-29 and Caco-2)161, and 
gingival (HGEC)162, Therefore, normal prostate epithelial cells, hPrEC, were 
used to determine if hBD-1 exhibits a bystander effect on neighboring cells 
(Figure 5-1A). 
Here, media exposed to hPrEC for 48 hours was collected and used to 
treat DU145 and PC3 cells for 24,48, and 72 hours. MTT analysis of DU145 
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Figure 5-1: Basic diagram of bystander studies~ (A) A diagram that 
demonstrates the bystander assay perionned using conditioned media from 
hPrEC. (8) A diagram illustrating the use of conditioned media from prostate 
cancer cell lines induced for hBD-1 expression. 
(A) 
Collect media @ 24h & 48h 
Treat prostate cancer cell lines 
(8) Plate & transfect donor cells 
Induce 24h & 48h 
000 









Trypan Blue Exclusion 
Hoechst 
FACS 
Figure 5-1: Basic diagram of bystander assays. 
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cells following a 48h exposure to hPrEC conditioned media revealed mixed 
results (Figure 5-2). It appears that the difference between control media and 
conditioned media ranged from no to moderately significant. Therefore, alternate 
methods were used to investigate whether hBD-1 exhibits a bystander effect on 
adjacent cells. 
Effect of conditioned media on membrane integrity 
To test the possibility of hBD-1 exhibiting a bystander effect with an 
alternate method, we used media conditioned by prostate cancer cells induced to 
express hBD-1 (Figure 5-18). Since the proposed mechanism of action of 
defensin peptides involves pore formation, recipient cells were exposed to the 
conditioned media for 24 or 48 hours prior to analysis of membrane integrity by 
confocal microscopy (Figure 5-3). Intact cells stained green due to the 
fluorescence of membrane permeable AD, whi,le cells with compromised 
membranes stained red due to the fluorescence of membrane impermeable EtBr. 
When DU145 cells were treated with media conditioned by DU145 cells, there 
was a slight accumulation of EtBr staining in hBD-1 exposed (A). However, 
LNCaP cells treated with media conditioned by DU145 cells did not demonstrate 
a difference in staining from control or pvgRXR exposed (8). Media conditioned 
by LNCaP was also used to treat LNCaP and did not demonstrate a difference in 
EtBr staining from pvgRXR exposed (C). This finding sl:lQgests that alterations to 
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Figure 5-2: Effect of conditioned media on cell viability_ An MTT assay was 
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Figure 5-2: Effect of conditioned media on cell viability_ 
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Figure 5-3: Effect of conditioned media on membrane integrity. Membrane 
integrity of recipient cells was analyzed by confocal microscopy 24 h after hBD-1 
induction. (A) DU145 conditioned media on DU145 recipient cells. (B) DU145 
conditioned media on LNCaP recipient cells. (C) LNCaP conditioned media on 
LNCaP recipient cells. Green staining indicates the localization of AO, red 
staining represents EtBr and yellow staining represents the co-localization of 
both AO and EtBr. Size bars = 10 j/M. 
(A) Control Media pvgRXR Media hBD-1 Media 
(8) 
(C) 
Figure 5-3: Effect of conditioned media on membrane integrity. 
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membrane integrity may occur in response to exposure of hBD-1 containing 
media in some cases. 
Effect of conditioned medium on trypan blue exclusion 
Similar to the previous experiment, trypan blue is a vital stain used to 
selectively color dead cells blue, while viable cells exclude the dye. Since it has 
been demonstrated that hBD-1 is cytotoxic to celis, dye exclusion was used to 
assess the effect conditioned media had on other cells to test the possibility of a 
bystander effect. As indicated in Figure 5-4, there was not a significant effect of 
conditioned media from DU145 or LNCaP on recipient cell lines. However, there 
was a minimal increase in hBD-1 exposed cells indicating a slight trend toward a 
potential bystander effect. 
Effect of conditioned media on the cell cycle 
The cell cycle is comprised of a series of checkpoints and phases through 
which proliferating cells progress. The cell cycle consists of the following: G1, 
presynthetic growth phase 1; S, DNA systhesis phase; G2 ; and M, mitotic phase. 
Quiescent cells are in a state called Go, however, most tissues consist of cells at 
various phases of the cell cycle. 
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Figure 5-4: Analysis of dye exclusion after exposure to conditioned media .. 
The effect of hBD-1 conditioned media on DU145 and LNCaP prostate cancer 
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Figure 5-4: Analysis of dye exclusion after exposure to conditioned media. 
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The most commonly utilized dye for DNA content and cell cycle analysis is PI, 
which intercalates into the major groove of double-stranded DNA and produces a 
highly fluorescent adduct. Here, FACS analysis was performed to assess 
whether hBO-1 conditioned media had any effect on donor or recipient cells. 
Neither the results at 24 hours (Figure 5-5) nor 48 hours (Figure 5-6) indicated a 
difference from the negative control, pvgRXR. 
Effect of conditioned media on cells 
Since we have shown hBO-1 induces apoptotic cell death with expression, 
Hoechst 33342 was used to assess the effect of hBD-1 on donors and recipients. 
Hoechst dyes bind to AT-rich regions of DNA that can be excited with a UV 
source. It has been observed that short exposures of cells to low concentrations 
of Hoechst dye strongly labels apoptotic cells 163,164. Therefore, we utilized this 
method as a method to assess the end-point of hBO-1 expression observed in 
prostate cancer cell lines. Donor cells induced for hBD-1 expression 
demonstrated a significant increase in condensed nuclei from pvgRXR and 
controls (Figure 5-7). Media from the 24 hour donors was exposed to DU145 
recipient cells for 24, 48, and 72 hours. We found that although there was not a 
significant difference from pvgRXR and controls, there appears to be a trend 
consistent with a potential effect (Figure 5-8). DU145 recipient cells exposed to 
media from 48 hour donors demonstrated a slight, but i~_significant increase in 
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Figure 5-5: Cell cycle analysis after treatment with 24h conditioned media. 
The effect of 24 hour conditioned media on the cell cycle was analyzed by flow 
cytometry. Data are presented as percentages of modeled events measured at 
each phase. 
Cell Cycle Phase 
Modeled 
Cell Type GO/1 G2/M S %CV Apoptosis Events 
DU145 NGM 78.22% 10.21% 11.57% 8.24% 0.11% 9548 
DU 145 Donors: 
24h DU 145 Control 56.75% 22.18% 21.06% 7.05% NO 9339 
24h OU145 pvgRXR 69.57% 21.22% 9.21% 9.58% 0.02% 9567 
24h DU145 hBD1 66.83% 23.41% 9.75% 10.29% 0.00% 9565 
DU 145 Recipients: 
24h OU145 NGM 78.87% 4.53% 16.60% 11.51% NO 584 
24h DU145 10 uM PonA 3.24% 0.00% 96.76% 2.64% NO 58 
24h DU145 H202 7.55% 0.00% 92.45% 2.58% NO 61 
24/24 DU:DU Control 5.35% 0.29% 94.37% 0.24% NO 53 
24/24 OU:OU pvgRXR NO ND NO NO NO NO 
24/24 DU:DU hB01 16.57% 0.00% 83.43% 3.78% 3.62% 67 
24/48 DU:DU Control 63.66% 18.63% 17.71% 10.79% NO 1652 
24/48 DU:DU pvgRXR NO NO NO NO NO NO 
24/48 DU:OU hB01 53.34% 43.43% 3.23% 12.19% NO 42 
24172 DU:OU Control NO NO NO NO NO NO 
24172 DU:OU pvgRXR NO NO NO NO ND ND 
24172 OU:OU hB01 NO NO NO NO NO NO 
LNCaP Recipients: 
24h LNCaP NGM 50.70% 25.07% 24.23% 9.20% NO 9278 
24h LNCaP 10 uM PonA 66.53% 16.73% 16.74% 8.99% NO 1501 
24h LNCaP H202 62.43% 19.36% 18.20% 9.55% 0.03% 9396 . 
24/24 DU: LN Control 60.70% 13.96% 25.35% 8.15% NO 841 
24/24 DU:LN pvgRXR 17.90% 1.21% 80.88% 1.36% ND 39 
24/24 OU:LN hBD1 52.06% 21.89% 26.05% 10.13% NO 16 
24/48 DU:LN Control 38.36% 0.00% 61.64% 8.96% NO 41 
24/48 OU:LN pvgRXR 21.11% 0.00% 78.89% 11.26% NO 17 
24/48 DU:LN hBD1 NO NO NO ND NO NO 
24172 OU:LN Control NO NO NO NO NO NO 
24172 OU:LN pvgRXR NO NO ND NO NO NO 
24172 OU:LN hBD1 NO NO NO NO NO NO 
Figure 5-5: Cell cycle analysis after treatmer),t with 24h conditioned media. 
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Figure 5-6: Cell cycle analysis after treatment with 48h conditioned media. 
The effect of 48 hour conditioned media on the cell cycle was analyzed by flow 
cytometry. Data are presented as percentages of modeled events measured at 
each phase. 
Cell Cycle Phase 
Modeled 
Cell Type GO/1 G2/M S %CV Apoptosis Events 
OU145 NGM 78.22% 10.21% 11.57% 8.24% 0.11% 9548 
OU145 Donors: 
48h OU145 Control 58.63% 20.56% 20.80% 9.24% NO 9469 
48h OU145 pvgRXR 69.81% 23.51% 6.67% 10.73% NO 1957 
48h DU145 hBD1 NO NO ND ND ND NO 
DU145 Recipients: 
48h OU145 NGM 61.67% 22.35% 15.97% 8.66% NO 9046 
48h DU145 H202 66-55% 14.88% 18.57% 8.69% NO 9142 
48/24 DU: DU Control 65.46% 19.46% 15.08% 9.20% NO 4089 
48/24 DU: DU pvgRXR 100.00% 0.00% 0.00% 7.00% NO 5 
481Z4 DU:DU hBD1 12.99% 0.00% 87.01% 0.30% 4.37% 50 
48/48 DU:DU Control NO NO 0.00% NO NO 0 
48/48 DU: DU pvgRXR 22.94% 5.74% 71-33% 0.66% NO 39 
48/48 DU: OU hBD1 51.95% 4.24% 43.81% 6.21% 0.70% 326 
48172 DU:DU Control 12.03% 2.59% 85.38% 0.72% NO 181 
48/72 DU: DU pvgRXR 56.38% 19.76%. 23.86% 10.61% 2.73% 868 
48/72 DU: DU hBD1 7.84% 0.00% 92.16% 0.22% 3.82% 160 
lNCaP Recipients: 
48h LNCaP NGM 83.56% 11.38% 5.07% 9.20% NO 841 
48h LNCaP H202 63.25% 0.25% 36.50% 5.04% NO 33 
48/24 DU:LN Control NO NO NO NO NO NO 
48/24 DU:LN pvgRXR 81.12% 18.88% 0.00% 13.2golo NO 23 
48/24 DU:LN hBD1 NO NO NO NO NO NO 
48/48 DU:LN Control 0.00% NO NO 0.00% 100.00% 3 
48148 DU:LN pvgRXR NO NO 0.00% NO NO 0 
48/48 DU:LN hBD1 NO NO NO NO NO ND 
48/72 DU: LN Control 89.72% 6-27% 4.00% 16.42% 3.47% 215 
48/72 DU: LN pvgRXR 83.48% 5.72% 10.80% 10.23% 0.77% 731 
48/72 DU: LN hBD1 82.17% 8.22% 9.61% 11.01% 1.57% 923 
Figure 5-6: Cell cycle analysis after treatment with 48h conditioned media. 
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Figure 5-7: Analysis of apoptosis in donor cells. (A) Microscopic analysis of 
condensed nuclei in DU145 cells induced for hBD-1 expression for 24 hours. (8) 
Graphical representation demonstrating the percentage of condensed nuclei in 
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Figure 5-7: Analysis of apoptosis in donor cells. 
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Figure 5-8: Analysis of apoptosis after exposure to 24h conditioned media. 
(A) Microscopic analysis of condensed nuclei in DU145 cells exposed to 24h 
conditioned media at 24; 48, and 72 hours. (8) Graphical representation 
demonstrating the percentage of condensed nuclei in DU145 cells exposed to 
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Figure 5-8: Analysis of apoptosis after exposure to 24h conditioned media. 
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apoptotic nuclei (Figure 5-9). Additionally, similar results were found for PC3 
cells under the same conditions (data not shown). 
DISCUSSION 
The field of tumor immunity has been rapidly expanding in recent years. 
There is increasing evidence that altered immune function may not only 
accompany, but even facilitate the development and progression of cancer. To 
date, numerous AMPs and other host-defense molecules have been shown to 
have altered expression profiles in a variety of cancers6. 56.165. 
Previously we demonstrated the high frequency of hBD-1 expression in 
prostate and renal carcinomas6 . The cancer-specific cytotoxicity of hBD-1 was 
recently shown in a renal cancer celiline57 • In addition, our studies have 
confirmed that late-stage prostate cancer cells induced to express hBD-1 
undergo a caspase-mediated cell death, while normal prostate cells and early-
stage prostate cancer cells do not56. 
It is known that hBD-1 exhibits antimicrobial properties by binding to the bacterial 
membrane and forming pores that ultimately result in death166 . However, the 
exact mechanism by which hBD-1 exhibits cytotoxicity toward cancer cells is 
unknown. To better understand the mechanism of cytotoxic action of hBD-1 in 
human cancer cell lines, we designed experiments to elucidate whether the 
secreted peptide acts in an autocrine or paracrine fashion. 
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Figure 5-9: Analysis of apoptosis after exposure to 48h conditioned media. 
(A) Microscopic analysis of condensed nuclei in DU145 cells exposed to 48h 
conditioned media at 24,48, and 72 hours. (8) Graphical representation 
demonstrating the percentage of condensed nuclei in DU145 cells exposed to 
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Figure 5-9: Analysis of apoptosis after exposure to 48h conditioned media. 
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Specifically, we performed an array of assays in an effort to determine if 
hBD-1 exhibited a bystander effect on adjacent cells. In our system we were 
unable to demonstrate a bystander effect attributed to the expression of hBD-1. 
However, several assays resulted in data that indicates a slight trend toward a 
potential bystander effect. 
There are several reasons why a bystander effect was not observed within 
our test parameters. The first possibility involves the proteolytic processing of 
the peptide. It is known the functionally active protein in host defense is the 36 
amino acid peptide81 , 118. Additionally, it has been shown that significant amounts 
of hBD-1 peptide are released into the lumen of the kidneys as a 47 amino acid 
pro-peptide that undergoes proteolytic cleavage to a variety of truncated 
forms118. Although the microbicidal activity of other forms of hBD-1 was reduced 
in some conditions, it has been shown that these effects were not observed with 
the biologically active 36 amino acid peptide74 . Given that the exact size of hBD-
1 peptide generated in our expression system is unknown, it is a possibility that 
there is a decrease in biological activity due to proteolytic processing. 
The observed trend toward a potential bystander effect may be due to the 
expression system used to induce hBD-1 in the cell lines. hBD-1 was cloned into 
the Ecdysone Inducible Mammalian Expression System (Invitrogen), a dual 
vector system that permits the regulation of gene expression. In this system, 
both subunits of a functional ecdysone receptor from Drosophila are 
constitutively expressed from the regulator vector, pvgRXR. The ecdysone-
responsive promoter (p-Jl-HSP) that ultimately drives the expression of hBD-1 is 
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located on the second inducible vector. In the presence of the inducer, Pon A, 
the functional ecdysone receptor binds upstream of the ecdysone responsive 
promoter and activates gene expression. Although expression is supposed to be 
ligand-induced, it has been shown that this system is leaky and allows for gene 
expression in the absence of the inducing agent167. 
Due to the leaky nature of the expression system, it was difficult to 
generate stable clones in the prostate cancer cell lines since hBO-1 is cytotoxic 
to them. Therefore, transient transfections were performed to evaluate hBD-1 
effect on the cultured cells. Although an estimation of transfection efficiency was 
completed to derive an average, there was variation between the experiments. 
Taken together, it is possible that the optimal transfection efficiency in this 
transient system was not achieved to observe a bystander effect. 
A final reason for the lack of bystander effect in the methods tested may 
be due to the concentration of hBD-1 present. It is believed that when a peptide 
is selective for a cancer cell a threshold concentration must be reached prior to 
membrane disruption91 . In the methods used there was not a quantitative 
analysis of hBD-1 in the conditioned media, thus, making it possible that the 
difference in responses between donor and recipient cells may be due to altered 
media concentrations of the peptide. Additionally, the experiments did not 
assess the degradation of the peptide to see if this potentially contributed to a 
decrease concentration of hBO-1 in the conditioned media exposed to recipient 
cells. 
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In summary, we utilized hPrEC which are believed to constitutively 
express hBD-1 and prostate cancer cell lines induced to express hBD-1 to test 
the possibility of a bystander effect. In donor DU145 and PC3 prostate cancer 
cells induced for hBD-1 expression, a clear cytotoxic effect was observed. 
However, the treatment of recipient cells with conditioned media did not generate 
similar results. Data indicate that although there is not a bystander effect under 
the conditions tested, there is a trend upward indicating the possibility of a 
bystander effect. Therefore, it may be interesting to study the potential bystander 
effect of hBD-1 under different conditions. 
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS 
142 
Prostate cancer continues to be the most common non-cutaneous cancer 
and a leading cause of death in American men25• A variety of factors increase 
the risk for development of prostate cancer, including diet, environment and 
genetics. Although the exact mechanism of prostate tumorigenesis is unknown, 
it is known that the molecular pathogenesis involves a series of pre-malignant 
changes that lead to the uncontrolled cell growth indicative of prostate cancer. 
Currently there are limited treatment methods that improve survival 
beyond localized prostate cancer153. Additionally, the clinical outcome of 
prostate cancer is closely related to the tumor grade and stage, with poorly 
differentiated tumors having a poor prognosis 131. In prostate cancer patients, 
tumor progression has been linked to an increase in immune suppression6. It 
has also been suggested that tumors escape destruction due to an imbalance 
between immune activation and suppression during tumor growth 132. However, 
little is known about specific components of the innate immune system that play 
a role in prostate tumor suppression. Therefore, the emergence of new 
molecular targets that have strong anti-tumor effects without corresponding host 
toxicity may prove to be an essential treatment modality in prostate cancer. 
The involvement of defensin proteins in cytotoxicity and cytolysis, with 
respect to tumor immunity, is gaining more attention. Defensins are a family of 3-
4 kDa polycationic peptides involved in host immunit/o. They are classified into 
subfamilies, a-, /3-, and 8-defensins, based on the connectivity of cysteine 
residues in the precursor gene structure74 . The a-defensins are predominantly 
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abundant in the granules of polymorphonuclear leukocytes and exhibit broad 
spectrum antimicrobial activity against Gram-negative and Gram-positive 
bacteria, fungi, and enveloped viruses7S, 79. On the other hand, p-defensins have 
been identified in epithelial cells and are mainly active against Gram-negative 
bacteria and yeast60,77. 
The core motif for p-defensins includes 9 highly conserved amino acid 
residues that probably serve as essential components of the primary structural 
motitB1, 168. To date, six hBDs have been identified that are constitutively 
secreted, hBD-1, or induced for secretion, hBDs 2-6, at the epithelial cell 
suriace84,85. Of particular interest in our lab was hBD-1, which was first isolated 
from the plasma of patients with renal disease in 199581 . Several N-terminally 
truncated molecular variants of hBD-1 have been identified from 36-47 amino 
acids in length. However, the 36 amino acid peptide is considered the 
biologically active form 74 
Previously Donald et al have shown the cancer specific loss of hBD-1 
expression in prostate and renal carcinoma tissue6 . Specifically, 82% of the 
malignant prostate tissue demonstrated little to no hBD-1 expression compared 
to adjacent benign tissue6 . In addition, the observed loss of expression occurred 
as early as PIN with adjacent benign tissue displaying normal glandular staining 
for hBD-1 6. 
These observations led to the hypothesis that hBD-1 may have anti-tumor 
activities and that its loss may contribute to prostate tumorigenesis. In this study, 
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we test the hypothesis that hBD-1 may have anti-tumor activities by 
characterizing its function in prostate cancer. Initial screening of benign prostate 
tissue and the primary prostate cell culture hPrEC revealed high levels of hBD-1 
expression. However, we observed a decrease or loss of hBD-1 expression in 
adjacent malignant prostate tissue, as well as in DU145, PC3 and LNCaP 
prostate cancer cell lines. 
Induction of hBD-1 expression in our prostate cancer cell lines caused a 
significant reduction in cell viability and proliferation in the late-stage prostate 
cancer cell lines, DU145 and PC3. To assess whether the effect was cytostatic 
or cytotoxic, we performed FACS analysis to measure cell death. After inducing 
hBD-1 in DU145 and PC3 cell lines, the number of cells undergoing early 
apoptosis and late apoptosis/necrosis totaled 59% and 44%, respectively, by 48 
hours. Our results demonstrated the cytotoxic activity of hBD-1 on DU145 and 
PC3 prostate cancer cells. 
The mechanism of cell death indicated in our cytotoxicity studies was 
apoptosis. To better understand the actions of hBD-1 in prostate cancer cells, 
we investigated whether hBD-1 induction resulted in caspase activation. Initial 
studies indicated the general activation of caspases in DU145 and PC3 cells. 
Analysis of specific caspases demonstrated that hBD-1 expression results in the 
activation of caspases 3, 8, and 9. In addition, there were alterations in the 
expression profiles of several pro- and anti-apoptotic factors. These findings 
suggest that hBD-1 expression may playa key role in determining the fate of 
cancer cells and, hence, tumor progression. 
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The proposed mechanism of antimicrobial action of defensin peptides 
involves the disruption of the microbial membrane due to the formation of 
pores80• To determine if hBD-1 expression altered the membrane integrity of the 
prostate cancer cells, EtBr uptake was examined by confocal analysis. Our 
results demonstrated permeable membranes in DU145 and PC3 cell induced for 
hBD-1 expression, while LNCaP did not have observable membrane alterations. 
This finding suggests that alterations to membrane integrity in response to hBD-1 
expression differ between early- and late-stage prostate cancer cells. 
Additionally, it provides the first line of evidence into the mechanism of hBD-1 
induced cell death. 
To further delineate the mechanism of hBD-1 cytotoxicity, we examined if 
the death observed was due to a bystander effect. Several groups have 
demonstrated the secretion of hBO-1 into the media of a variety of epithelial cell 
lines 160,161. Therefore, hPrEC generated conditioned media was used to 
determine if hBO-1 exhibits a bystander effect. The results of the initial study 
revealed a range from insignificant to significant reduction in cell viability after 
exposure to the conditioned media. Due to the variation in the results and the 
lack of concrete evidence supporting the secretion of hBD-1 by hPrEC, alternate 
methods to generate conditioned media were employed. 
As an alternate method to generate conditioned media, prostate cancer 
cell lines were induced for hBD-1 expression and the media was collected at 
various time points to treat non-hBD-1 expressing prostate cancer cells. We 
have previously demonstrated that hBD-1 expression in DU145 and PC3 results 
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in a decrease in cell viability, an increase in membrane permeability and 
apoptosis. Therefore, we assessed recipient cells following treatment with 
conditioned media by dye exclusion, AO/EtBr staining, and Hoechst staining to 
observe the effects, if any, to cell vitality, membrane integrity and nuclear 
condensation. Although the results did not indicate a bystander effect within the 
experiment parameters, there was a minimal increase in staining in each of the 
assays indicating a slight trend toward a potential bystander effect. In addition, 
cell cycle analysis following treatment with hBD-1 conditioned media was 
performed. However, the results indicated no difference from the negative 
control pvgRXR conditioned media. 
There are several reasons why a bystander effect was not attributed to the 
expression of hBD-1 in our system. Since it is unknown what form of the peptide 
is expressed in these experiments, it is possible that differences in the proteolytic 
processing of the peptide have reduced the activity. Also, the concentration of 
peptide in the media is unknown. It has been shown that synthetic hBD-1 
peptide caused a decrease in cell viability in bladder cancer cells at 50pg/m157. 
The trend toward; but lack of, a bystander effect may be due to the fact that the 
threshold concentration of hBD-1 peptides was never reached to see optimal 
results. In addition, a significant limitation to concentration of hBO-1 in our 
system is the transient nature of our transfections. 
Taken together, our data support the hypothesis that hBD-1 is a tumor 
suppressor gene. Also, the data indicate the loss of hBD-1 in the surrounding 
tissue in may create an environment that promotes the progression of prostate 
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cancer. Due to the decreased expression of a host defense peptide in cancer, 
there is a suggestion that defensins may contribute to tumor immunity. 
The anti-tumor effect of defensins is an emerging field. Preliminary 
experiments by Huang et al. demonstrated the slower growth of tumors injected 
with hBD-2 vectors compared to control possibly due to an antitumor effect of 
hBD_2169. Also, others have shown the differential gene expression profiles of 
defensins in a variety of cancers 115,116. Therefore, additional studies of the anti-
tumor effect of defensins are necessary to delineate the specific contribution of 
defensins to tumor immunity. 
The scope of this study was limited to characterizing the effects of hBO-1 
in prostate cancer cells. However, there are several key experiments that would 
Significantly contribute this particular area of research. First, the generation of a 
better expression system is essential. The ability to perform quality experiments 
in the future will require stable clones that can be induced without accompanied 
leakiness of gene expression. Also, a triple stain experiment to verify which cells 
are undergoing apoptosis after exposure to hBD-1 containing media would 
provide further insight into the cytotoxic mechanism of this defense peptide. 
Ultimately, in vivo experiments that investigate the anti-timor effects of hBD-1 will 
aid in determining the clinical relevance of our findings. 
In summary, this data demonstrates the induction of hBD-1 expression 
resulted in rapid cell death in the late-stage prostate cancer cell lines, PC3 and 
DU145, but had no effect on the early-stage prostate cancer cell line, LNCaP. 
148 
With this, we provide the experimental evidence that hBD-1 may playa specific 
role in tumor suppression of advanced prostate cancer. Furthermore, these data 
support the potential utility of hBD-1 as a therapeutic agent for late-stage 
prostate cancer without cytotoxic effects to the host. 
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